

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

An Exploratory Clinical Study on Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure (HERE-CHF)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023923
Article Type:	Protocol
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	Li, Jiahui; China-Japan Friendship Hospital, Cardiology Yang, Peng; China-Japan Friendship Hospital, Integrative Cardiology Fu, Dongliang; China-Japan Friendship Hospital, Integrative Cardiology Ye, Xiaojun; China-Japan Friendship Hospital, Cardiology Zhang, Lifang; China-Japan Friendship Hospital, Cardiology Chen, Gang; China-Japan Friendship Hospital, Rehabilitation Yang, Yiyun; China-Japan Friendship Hospital, Cardiology Luo, He; China-Japan Friendship Hospital, Cardiology Chen, Li; China-Japan Friendship Hospital, Phase I Clinical Ward of Clinical Trial Shao, Mingjing ; China-Japan Friendship Hospital, Integrative Cardiology Li, Chunyan; China-Japan Friendship Hospital, Integrative Cardiology Liu, Yi; China-Japan Friendship Hospital, Integrative Cardiology Zhou, Ying; China-Japan Friendship Hospital, Cardiology Jiang, Hong; China-Japan Friendship Hospital, Integrative Cardiology Li, Xianlun; China-Japan Friendship Hospital, Cardiology, Integrative Cardiology
Keywords:	Heart failure < CARDIOLOGY, REHABILITATION MEDICINE, Telemedicine < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™
Manuscripts

1
2
3
4 **An Exploratory Clinical Study on Effect of Home-based Cardiac**
5
6 **Exercise Rehabilitation with Remote Electrocardiogram Monitoring in**
7
8 **Patients with Chronic Heart Failure (HERE-CHF)**
9

10
11
12
13 Jiahui Li^{1*}, Peng Yang^{2*}, Dongliang Fu², Xiaojun Ye¹, Lifang Zhang¹, Gang Chen³,
14
15 Yiyun Yang¹, He Luo¹, Li Chen⁴, Mingjing Shao², Chunyan Li², Yi Liu², Ying Zhou¹,
16
17 Hong Jiang^{2*}, Xianlun Li^{1,2*}
18

19
20 ¹Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China;

21
22 ²Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing

23
24 100029, China; ³Department of Rehabilitation, China-Japan Friendship Hospital,

25
26 Beijing 100029, China; ⁴Phase I Clinical Ward of Clinical Trial Research Center,

27
28 China-Japan Friendship Hospital, Beijing 100029, China.
29

30
31
32 * Jiahui Li and Peng Yang are joint first authors.

33
34
35 ^{*}Correspondence: Xianlun Li and Hong Jiang are both corresponding authors.

36
37 Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com.

38
39 Hong Jiang: Tel: + 86 15811227722, E-mail: drjh68@163.com.

Abstract for protocol

Introduction

Patients with Chronic heart failure (CHF) can benefit from exercise rehabilitation (ER) with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Despite its reported benefits, only a limited number of patients with CHF attend ER because of poor adherence and improper exercise may even cause adverse events. Remote electrocardiogram monitoring system (REMS) has the potential to overcome these barriers. We hypothesize that home-based cardiac ER using REMS in CHF patients is effective compared with conventional ER without monitoring.

Methods and Analysis

This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness of home-based ER with REMS in the management of CHF, which has a target enrollment of 120 stable CHF patients (Left Ventricular Ejection Fraction <50%, NYHA classes I to III). Patients are randomized to either REMS rehabilitation group or the conventional rehabilitation group. In the REMS exercise group, patients wearing monitors when exercising to ensure that exercise intensity is within the ranges set for them. REMS will also detect risky arrhythmia and give an early warning to both the patients and their doctors. The training intensity is not monitored in the conventional rehabilitation group. The primary outcome measure is exercise capacity improvement measured by peak oxygen uptake.

Ethics and Dissemination

This study was approved by Ethics Committee of China-Japan Friendship Hospital for Clinical Research (No. 2017-SFZX-9, 10 Aug 2017), registered on 22 August 2017 at the website of Chinese Clinical Trial Registry (ChiCTR-RNR-17012446) and conducted in accordance with the principles of Good Clinical Practice (GCP) and the Helsinki Declaration. All participants must sign a written informed consent before randomization.

Strengths and limitations of this study

1. Our wearable monitor in this study has been approved by Food and Drug Administration in Shandong province of China (Certificate No. Shandong Medical Device Registration Approval 20172210878).
2. Our REMS will help to increase CHF patients' adherence and reduce risk factors when exercising, which may further enhance the effectiveness of ER.
3. The **HERE-CHF** study will provide new insights in the effect of home-based cardiac ER guided by REMS.
4. The major limitation of this single-center study is the small sample size.
5. A long-term follow-up may be also needed. Extending the exercise out to 6 months may give us better data on adherence.

Keywords: Cardiac exercise rehabilitation, Telerehabilitation, Chronic heart failure, Remote Electrocardiogram Monitoring System

Background

Heart failure (HF) is a complex clinical syndrome caused by abnormal cardiac structure or function which results in impaired ventricular filling or ejection ability. It is the terminal stage of various cardiovascular diseases, which has become the global public health problem of great concern. The prevalence of HF in the whole population is approximately 1.5%-2% and 6%-10% over 65 years of age^[1]. More and more individuals are surviving an acute cardiovascular attack due to modern therapies now and the concomitant burden of chronic HF (CHF) is also increasing worldwide. At present, there are 8-10 million patients with HF in China, and the prevalence rate increases significantly with age according to China Cardiovascular report 2017^[2]. The 5-year survival rate of HF patients with clinical symptoms is 50% , similar to that of malignant tumors^[1]. Repeated visits and hospitalizations of HF patients bring heavy economic burdens to individuals, families and society.

Many HF patients on optimal cardiovascular drug therapy still suffer from dyspnea and exercise intolerance. In addition to pharmacological treatment and device therapy, successful cardiac rehabilitation is a valuable intervention for improving aerobic fitness and overall health status in patients with HF. There is a growing consensus that exercise has a beneficial effect on patients with cardiovascular disease, even for those with severely impaired cardiac function. HF patients can benefit from proper exercise with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Exercise training is a core component of primary and secondary prevention, which has been recommended by relevant international professional associations^[3-6].

Despite its reported benefits, a limited number of patients attend exercise rehabilitation (ER) on a regular basis mainly because of poor patients' adherence. Furthermore, improper exercise may even cause adverse cardiovascular events such as myocardial infarction, tachyarrhythmias and sudden death. HF-A Controlled Trial Investigating Outcomes of exercise training (HF-ACTION)^[7] is the largest multicenter clinical study of ER in HF, which randomly assigned 2331 patients to

1
2
3 either exercise training or usual care. Only Forty-two percent of subjects in their
4 cohort completed all three of their scheduled follow-up exercise tests and 33% and 25%
5 completed two and one of their scheduled follow-up exercise tests, respectively.
6
7 Given the observed effect between higher adherence and improved outcomes, it is
8 more important to provide cardiac ER programs which can achieve increased
9 adherence to the exercise intervention [8].
10
11

12
13
14 Cardiac telerehabilitation using monitoring devices and remote communication with
15 patients has now been used more and more in the long-term management of
16 cardiovascular diseases outside the hospital environment. Providing objective
17 feedback data and allowing patients to track their own progress can increase patients'
18 self-management skills and thus improve their adherence. It is convenient and can
19 reduce anxiety; improve the quality of life, compliance and prognosis of patients with
20 low medical costs compared with conventional ER [9-13].
21
22

23
24
25 This study is a prospective, randomized, parallel controlled clinical trial to evaluate
26 the effectiveness and safety of home-based ER under the guidance of remote
27 electrocardiogram (ECG) monitoring system (REMS) in the management of CHF.
28
29

30
31 This article describes the design and rationale of the **HERE-CHF** trial supported by
32 China Capital Health Development Research Special Fund of 2018.
33
34

35 **Methods/design**

36 *Aims*

37
38 The primary objective of **HERE-CHF** trial is to test the hypothesis that
39 individualized home-based cardiac ER using REMS to guide patients with LV systolic
40 dysfunction【LVEF<50%, New York Heart Association (NYHA) classification I-III 】
41 is effective and safe with the advantages of standardization and easy implementation
42 compared with conventional ER without monitoring. The primary outcome measure is
43 exercise tolerance measured by peak oxygen uptake (VO₂) at baseline and three
44 months. Secondary outcome measures include 6-min Walk Test (6MWT), NYHA
45 classifications, echocardiographic parameters, cardiac biomarkers, major adverse
46 cardiovascular events (MACE), quality of life, psychological state and patients'
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 compliance.

4 5 ***Design***

6
7 A flow chart of the study design is shown in Figure 1. The study strategy is registered
8 on the website of Chinese Clinical Trial Registry (ChiCTR-RNR-17012446,
9 registered on 22 August 2017), constructed and presented according to the
10 recommendations for Interventional Trials (SPIRIT) [14].
11
12

13 14 ***Study sites and Patient population***

15
16 Patients are recruited consecutively from the Cardiology Department of China-Japan
17 Friendship Hospital in Beijing, China. Patient selection criteria are listed in Table 1.
18 CHF had to be documented from at least one echocardiogram performed within the
19 previous 6 weeks under clinically stable conditions.
20
21

22
23 **HERE-CHF** trial has a target enrollment of 120 stable CHF patients (LVEF<50%,
24 NYHA classes I to III) based on a predefined set of inclusion and exclusion criteria
25 (Table I). Patients must have an LV ejection fraction (LVEF) of <50% on a baseline
26 echocardiogram. Stable optimal pharmacologic therapy according to the published
27 guidelines for 6 weeks before enrollment is strongly advocated. If patients are not
28 treated with optimal HF pharmacologic treatment as defined by the American College
29 of Cardiology(ACC)/American Heart Association (AHA) HF guidelines (ie,
30 angiotensin-converting enzyme inhibitors and β -blockers), then trial personnel must
31 document the underlying reason (eg, drug intolerance).
32
33
34
35
36
37
38
39
40

41 42 ***Exercise testing***

43 Prerandomization cardiopulmonary exercise testing (CPET) is used to determine
44 whether patients can exercise safely as defined by the American Association of
45 Cardiovascular and Pulmonary Rehabilitation guidelines, including checking for
46 abnormal blood pressure responses, early ischemic changes, and significant
47 arrhythmias. Exercise testing is repeated 3 month after randomization for all patients.
48
49 The primary method used for exercise testing is cycling, consistent with AHA
50 guidelines and with other trials that have assessed exercise capacity in patients with
51 HF.
52
53
54
55
56

Randomization

After providing informed consent and undergoing baseline testing (echocardiogram and CPET), patients are randomized at the enrolling center in a 1:1 ratio to either REMS rehabilitation arm or the conventional rehabilitation arm.

Trial structure

The trial structure of the study is described in the Table 2.

REMS

Inticare-MC-06 wearable ECG monitor (Elephant Medical Electronic Technology, Jining, China), which is approved by Food and Drug Administration in Shandong province of China (Certificate No. Shandong Medical Device Registration Approval 20172210878) is a medical-grade portable cardiac monitor which looks like a smaller “Band-Aid” and can collect single-lead ECG data for 48 hours. It can provide cardiac care service through "Hardware+Software+ Cloud + Doctor" program, and support arrhythmia automatic trigger and One-Tap SOS. Its goal is to reduce health care cost, detect arrhythmia earlier, get treatment timely and provide better service for heart health. Inticare-MC-06 heart health monitor solution includes 5 parts: inticare-M1 wearable ECG monitor, mobile terminals (such as smart phones), cloud data storage platform (Tianjin AILife Medical Technology, China), cardiologists and monitoring reports. Wearable ECG monitor will be pasted on the chest through one-piece electrodes and transfer the ECG data to the mobile phone application via lower power bluetooth smart technology. The unique algorithm can analyze the data in real time and detect suspected arrhythmia disease, then give the alarm and transfer data to cloud for doctors to check and confirm the disease. In addition, when you feel chest stuffy, heart palpitations and dizzy, you can mark the ECG data during this 1 minute through One-Tap Marking button and send the data to cloud for doctors to check and give corresponding diagnosis. At the end of the monitoring, inticare-M1 can provide the monitoring report.

Interventions

All the patients initiate an exercise training program following the principles of

1
2
3 exercise prescription as recommended by the American College of Sports Medicine
4 (ACSM) and the AHA. The exercise stage order can be warm-up, main exercise, and
5 cool-down. For the warm-up and cool-down, walking or light stretching is
6 recommended. The main exercise is walking. Exercise training initially begins in a
7 supervised setting and then transitions to a home-based regimen(Table 3 and table 4).
8
9
10
11
12 The supervised training phase of the trial consists of 12 supervised training sessions,
13 with a goal of 3 sessions per week. Patients have up to 1 month to complete the 12
14 sessions before transitioning to the home exercise phase of the trial. Patients are asked
15 to exercise 5 times per week during the home exercise phase, totally 8 weeks. The
16 exercise training protocol was designed such that patients begin exercising at a low
17 intensity and then increase to a moderate intensity when they are able. The trial
18 protocol allows patients to walk independently.
19

20
21 In the REMS exercise training arm, patients wear Inticare-MC-06 ECG monitor when
22 exercising at home to ensure that exercise intensity is within the ranges set for them
23 and are instructed on how to monitor their own exercise training at the beginning of
24 the trial. During the exercise, the monitor can evaluate whether patients reach the
25 intensity and time of the preset exercise prescription according to the heart rate. If the
26 speed is not enough or the intensity exceeds the preset value, the system uses voice
27 prompt to remind the patient to adjust the intensity, including speed and time course,
28 so as to ensure the patient to exercise according to the prescription. If a cardiogram
29 such as arrhythmia occurs during exercise, the system will alert the patient to stop or
30 suspend exercise, or adjust the intensity of exercise, and upload it in real time. The
31 data will be transformed to the data center, while specialist will give an analysis for
32 that report. System will give an early warning to both the user and their doctors if the
33 arrhythmia event they get is risky. Doctors can have a check of the data belong to
34 their patient outside hospitals, know about their condition and give advice in time.
35

36
37 The heart rate reserve (HRR) method is used to guide exercise intensity. Peak heart
38 rate is derived from a patient's most recent exercise test, and the resting heart rate is
39 taken after 5 minutes of quiet seated rest. For the first 6 supervised training sessions,
40
41
42
43
44
45
46
47
48
49
50

1
2
3 the training heart rate range is computed at 60% of the HRR (resting heart rate + 0.6
4 [peak heart rate resting heart rate]). Then training intensity is increased to 70% of the
5 HRR for the rest of the supervised exercise training sessions. For the home-based
6 exercise training phase, patients are asked to perform 40 minutes of aerobic exercise.
7 In the REMS training arm, the training intensity should be maintained at 60% to 70%
8 of the HRR. While during the whole phase of the conventional rehabilitation arm, the
9 training intensity is not monitored.

16 ***Outcome assessments***

17 The primary outcome measure is exercise capacity improvement measured by VO_2
18 (baseline vs 3 m). The secondary outcome measures are: (1) difference in the meters
19 walked in the 6MWT; (2) improvement in heart function assessed by NYHA
20 classifications; (3) improvement in echocardiographic parameters of systolic and
21 diastolic function; (4) changes in biomarkers, including brain natriuretic peptide (BNP)
22 / N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and Troponin-T/I; (5)
23 changes in major adverse cardiovascular events (MACE) including worsening HF
24 event, HF hospitalization, myocardial infarction, stroke, revascularization and
25 cardiovascular mortality; (6) qualitative evaluation of patients' compliance to the
26 rehabilitation program. The investigators will also use several validated psychometric
27 instruments to measure health-related quality of life and depression. These
28 measurements include HF Symptom Scale, Minnesota Living with Heart Failure
29 Questionnaire (MLHFQ), 36-Item Short Form Health Survey (SF-36), Beck
30 Depression Inventory-II (BDI-II) and General Self-Efficacy Scale (GSE).

45 ***Withdrawal***

46 According to Ethics Committee of China-Japan Friendship Hospital for Clinical
47 Research legislations, we inform the patients about their rights as subjects in a
48 scientific trial and about their discontinuation rights. We do this to make patients
49 consider participation thoroughly to diminish the likelihood of their dropping out.
50 Patients can withdraw from the trial at their own request or at the request of their legal
51 representative at any time. Every withdrawal was recorded in the patient's health
52
53
54
55
56
57
58
59
60

1
2
3 record.

4 5 ***Data collection, management, and analysis***

6 We collect and manage study data using HF Rehabilitation-CARELAND database
7 (Beijing Cardiar Technology, China). Only relevant staff have logged access to the
8 key file. The principal investigator has a responsibility to secure and monitor data
9 collection and interpretation.
10
11
12
13

14 15 ***Adverse events monitoring***

16 All adverse events that occurred during the 3-month study observation period will be
17 reported in the final paper. A serious adverse event is defined as any untoward
18 medical occurrence resulting in hospitalization or which results in a life-threatening
19 problem, death, or disability. Adverse events will be defined as any untoward
20 occurrences in study participants, potentially related to implementation of the study
21 protocol. All serious and unexpected adverse events will be reported to the Ethics
22 Committee as required.
23
24
25
26
27
28

29 30 ***Sample size***

31 The target enrollment for the trial is 120 patients. A total of 500 patients with CHF
32 (NYHA grade I-III) are treated in our hospital every year , which can be used as a
33 screening sample. Calculated according to the lower screening rate (50%) and the
34 designed entry criteria, the sample size that can be completed is estimated to be 100
35 patients. Referring to the previous foreign literature, the compliance of ER in 3
36 months is 70-80%. The initial screening sample size of this study is at least 120 cases,
37 60 cases in each group.
38
39
40
41
42
43

44 45 ***Statistical analysis***

46 The clinical data management platform of China-Japan Friendship Hospital is
47 commissioned to create SAS 9.4 software to generate random concealment tables.
48 Masked envelopes will be produced by random concealment and participants are
49 admitted by 1:1 random principle. After screening for the inclusion and exclusion
50 criteria, the patients are randomly enrolled in the REMS rehabilitation group or the
51 conventional rehabilitation group according to the time order of the patients' entry.
52
53
54
55
56
57

1
2
3 The number of each subject remains unchanged during the course of the study. All
4 statistical tests will be 2-tailed. All data are presented as the mean±the standard
5 deviation (SD). Comparison of numerical variables between the study groups is made
6 using Student's t-test for independent samples in comparing 2 groups when normally
7 distributed and Mann–Whitney U-test for independent samples when not normally
8 distributed. P<0.05 is considered significant.
9

14 ***Patient and Public Involvement***

15
16 Enrollment of patients has started in April 2018. Patients are recruited consecutively
17 from the outpatient clinic of Cardiology Department and Integrative Cardiology
18 Department in China-Japan Friendship Hospital by the doctors in the study.
19

22 **Discussion**

23
24 **HERE-CHF** evaluates the effect of a cardiac telerehabilitation intervention that
25 combines modern technology (sensor technology, internet and remote consultation)
26 with evidence-based ER guidance strategies including prevention of adverse events
27 when exercising. The objective of this study is to investigate whether home-based
28 cardiac ER using REMS is superior to conventional ER without monitoring in CHF
29 patients. We hypothesize that this intervention will result in improved physical
30 activity levels and better quality of life.
31

32
33 Home-based cardiac rehabilitation is a method to improve participation rate of ER in
34 HF patients. Whether exercise prescription can be efficiently performed and the safety
35 in exercise are two main issues in home-based ER. While exercise intensity is the key
36 of exercise prescription because the exercise has to be appropriate. Heart rate is the
37 most important factor to monitor the patient's exercise intensity. Our wearable ECG
38 monitor can evaluate whether patients reach the intensity according to the heart rate
39 and remind the patients in time so as to ensure that exercise intensity is within the
40 preset range. REMS will also detect risky arrhythmia and give an early warning to
41 both the patients and their doctors, which can encourage patients to overcome fear and
42 adhere to exercise. The use of our REMS offers a prospect for the delivery and
43 expansion of home-based cardiac ER programs in HF patients beyond the supervised
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 setting and will help to increase adherence, reduce risk factors and improve
4 benefit-cost ratio , which may further enhance the effectiveness of ER.
5

6
7 CPET is useful to evaluate patient exercise capacity and exertional symptoms and can
8 offer numerous physiologic parameters. Multiple CPET-derived variables have been
9 assessed for their association with mortality in systolic HF patients and peak VO_2 is
10 shown to be the strongest predictor of mortality ^[15]. Therefore we select it as the
11 primary outcome measure in CR-HERES-CHF. The choice of the 6MWT as a
12 secondary outcome measure due to its useful prognostic information similar to peak
13 VO_2 ^[16]. 6MWT is less expensive and much more convenient in comparison to the
14 nontrivial costs of CPET with its distinctive value as a measure of routine activity.
15 Quality of life and psychological state are important in the evaluation of home-based
16 ER, which are also included in our study.
17
18
19
20
21
22
23
24
25

26 **Conclusion**

27
28 The **HERE-CHF** study will provide new insights in the effect of home-based cardiac
29 ER guided by REMS. Our REMS will help to increase HF patients' adherence and
30 reduce risk factors, which may further enhance the effectiveness of ER.
31
32

33 **Acknowledgements**

34
35
36 The authors thank all the patients advisers and students for their assistance in the
37 study.
38
39

40 **Funding**

41
42 This work is financially supported by China Capital Health Development Research
43 Special Fund (2018-2-4064) .The funding source does not influence or comment on
44 planned methods, protocol, data analysis, or the draft report.
45
46
47

48 **Competing interests**

49
50 The authors declare that they have no competing interests.
51

52 **Ethics approval and consent to participate**

53
54 This study was approved by Ethics Committee of China-Japan Friendship Hospital for
55
56
57

Clinical Research (No. 2017-SFZX-9, 10 Aug 2017), registered on 22 August 2017 at the website of Chinese Clinical Trial Registry (ChiCTR-RNR-17012446) and conducted in accordance with the principles of Good Clinical Practice (GCP) and the Helsinki Declaration. All participants must sign a written informed consent before randomization.

References

1. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2007 Dec; 35(12):1076-95.
2. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, Wu ZS, Li HJ, Gu DF, Yang YJ, Zheng Z, Jiang LX, Hu SS Representative group of Chinese cardiovascular diseases report. Report on cardiovascular diseases in China (2017). *Chinese Circulation Journal*. 2018; 33(1):1-7.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013 Oct 15;62(16):e147-239.
4. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2014. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2014 Feb;42(2):98-122.
5. Chinese Rehabilitation Medical Association Professional Committee of Cardiovascular Diseases; Committee of Cardio-Cerebral-Vascular Diseases of GSC. Chinese expert consensus on cardiac rehabilitation for patients with chronic stable heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2014 Sep;42(9):714-20.

- 1
2
3 6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
4 González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
5 Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
6 Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document
7 Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic
8 heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart
9 failure of the European Society of Cardiology (ESC). Developed with the special
10 contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016
11 Aug;18(8):891-975.
12
13
- 14 7. Keteyian SJ, Isaac D, Thadani U, Roy BA, Bensimhon DR, McKelvie R, Russell SD,
15 Hellkamp AS, Kraus WE; HF-ACTION Investigators. Safety of symptom-limited
16 cardiopulmonary exercise testing in patients with chronic heart failure due to severe left
17 ventricular systolic dysfunction. *Am Heart J*. 2009 Oct;158(4 Suppl):S72-7.
18
19
- 20 8. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training
21 Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac
22 Rehabilitation: A Systematic Review and Meta-regression. *Sports Med Open*. 2017 Dec;
23 3(1):19.
24
25
- 26 9. Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative
27 models of cardiac rehabilitation: a systematic review[J]. *Eur J Prev Cardiol*. 2015 Jan;
28 22(1):35-74.
29
30
- 31 10. Lee Y, Lee J, Seo H, Kim K, Min D, Lee J, Choi J. Effects of Home-based Exercise
32 Training with Wireless Monitoring on the Left Ventricular Function of Acute Coronary
33 Syndrome Patients. *J Phys Ther Sci*. 2013 May;25(5):631-3.
34
35
- 36 11. Chung H, Ko H, Thap T, Jeong C, Noh SE, Yoon KH, Lee J. Smartphone-Based
37 Cardiac Rehabilitation Program: Feasibility Study. *PLoS One*. 2016 Aug
38 23;11(8):e0161268.
39
40
- 41 12. Hwang R, Bruning J, Morris NR, Mandrusiak A, Russell T. Home-based
42 telerehabilitation is not inferior to a centre-based program in patients with chronic heart
43 failure: a randomised trial. *J Physiother*. 2017 Apr;63(2):101-107.
44
45
46
47
48
49
50
51
52
53
54
55
56
57

- 1
2
3 13. Di Lenarda A, Casolo G, Gulizia MM, Aspromonte N, Scalvini S, Mortara A, Alunni G,
4 Ricci RP, Mantovan R, Russo G, Gensini GF, Romeo F. The future of telemedicine for
5 the management of heart failure patients: a Consensus Document of the Italian
6 Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology
7 (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). *Eur Heart*
8 *J Suppl.* 2017 May;19(Suppl D):D113-D129.
- 9
10
11
12
13
14 14. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new
15 guidance for content of clinical trial protocols. *Lancet.* 2013; 381(9861):91–2.
- 16
17
18 15. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, Leifer ES, Fleg
19 JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, O'Connor CM, Ehrman JK,
20 Walsh MN, Ewald G, Bensimhon D, Russell SD; HF-ACTION Investigators. Variables
21 Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in
22 Chronic Systolic Heart Failure. *J Am Coll Cardiol.* 2016 Feb 23;67(7):780-9.
- 23
24
25
26
27 16. Daniel E. Forman, Jerome L. Fleg, Dalane Kitzman, Clinton A. Brawner, Ann Swank,
28 Robert McKelvie, Robert Clare, Stephen J. Ellis, Mark E. Dunlap, Vera Bittner. 6
29 Minute Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary
30 Exercise Testing in Ambulatory Outpatients with Systolic Heart Failure. *J Am Coll*
31 *Cardiol.* 2012 Dec 25; 60(25): 2653–2661.
- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. HERES-CHF trial inclusion and exclusion criteria

Inclusion criteria

1. Aged 18-75 years old;
2. chronic heart failure (NYHA I-III); LVEF<50% in 6 weeks before randomization;
3. in stable condition after heart failure standard drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device), no fluid retention, constant weight;
4. able to perform exercise rehabilitation;
5. clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

1. exercise rehabilitation can not be carried out due to physical disability and contraindication;
 2. with a contraindication to cardiopulmonary exercise test;
 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid artery or other major vascular surgery; percutaneous coronary intervention (PCI) or carotid artery angioplasty; sustained ventricular tachycardia or fibrillation;
 4. coronary revascularization or heart transplantation is planned;
 5. persistent atrial arrhythmias ; ventricular arrhythmias were not effectively controlled (using an antiarrhythmic drug or an implantable defibrillator);
 6. uncorrected primary obstructive or severe regurgitant heart valve disease, restrictive or hypertrophic cardiomyopathy;
 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker implantation; need implantable device therapy for heart failure;
 8. obstructive or bronchospasm lung disease (such as asthma, bronchitis, etc) needing oral or inhaled bronchodilator or glucocorticoids therapy;
 9. pregnant or lactating women and those planning to conceive during the trial;
-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

-
- 10. cancer or other systemic diseases with an expected survival of less than 12 months;
 - 11. other clinical trial drugs were taken or in other medical device trial within 30 days before admission;
 - 12. unable to participate in this study after the clinical evaluation by investigators.
-

For peer review only

Table 2 Trial structure of the study

Time Assessment	Screening (-14~1d)	Exercise Rehabilitation in Clinic			Exercise Rehabilitation at Home	
		T0 Visit 1 Baseline	T1 Visit 2 2 nd weekend	T2 Visit 3 4 th weekend	T3 Visit 4 8 th weekend	T4 Visit 5 12 th weekend
medical history	√					
Inclusion/Exclusion Form	√					
Consent Form	√					
Comorbidity	√	√	√	√	√	√
Concomitant medication	√	√	√	√	√	√
Physical examination	√	√	√	√	√	√
Troponin T/I		√				√
BNP/NT-proBNP		√				√
Electrocardiogram	√	√		√	√	√
Holter	√					√
NYHA classification	√	√		√	√	√
Echocardiography	√	√				√
CPET	√					√
6MWT		√				√

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Heart failure symptom scale		√				√
MLHFQ		√				√
SF-36		√				√
BDI-II		√				√
GSE		√				√
Compliance				√	√	√
Adverse event			√	√	√	√
Monitor and APP training		√				

The time window for each visit is ±3d. MLHFQ: Minnesota Living with Heart Failure Questionnaire. SF-36: 36-Item Short Form Health Survey. BDI-II: Beck Depression Inventory. GSE: General Self-Efficacy Scale.

Table 3. Exercise training program in remote ECG monitoring system rehabilitation group

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	2	3	15-30	60	walk
supervised by Rehabilitation specialist	Clinic	2	3	15-30	70	walk
Supervised by remote ECG monitoring	home	8	5	40	60-70	walk

Table 4. Exercise training program in conventional rehabilitation group without monitoring

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	4	3	15-30	without monitoring	walk
Symptom-Limited, self-adaption	home	8	5	40	without monitoring	walk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1 Study flow chart. CPET: cardiopulmonary exercise testing. 6MWT:6-min Walk Test.

For peer review only




Figure 1 Study flow chart.

170x233mm (144 x 144 DPI)

BMJ Open

Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure (HERE-CHF) : Study Protocol for a Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023923.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Sep-2018
Complete List of Authors:	Li, Jiahui; China-Japan Friendship Hospital, Cardiology Yang, Peng; China-Japan Friendship Hospital, Integrative Cardiology Fu, Dongliang; China-Japan Friendship Hospital, Integrative Cardiology Ye, Xiaojun; China-Japan Friendship Hospital, Cardiology Zhang, Lifang; China-Japan Friendship Hospital, Cardiology Chen, Gang; China-Japan Friendship Hospital, Rehabilitation Yang, Yiyun; China-Japan Friendship Hospital, Cardiology Luo, He; China-Japan Friendship Hospital, Cardiology Chen, Li; China-Japan Friendship Hospital, Phase I Clinical Ward of Clinical Trial Shao, Mingjing ; China-Japan Friendship Hospital, Integrative Cardiology Li, Chunyan; China-Japan Friendship Hospital, Integrative Cardiology Liu, Yi; China-Japan Friendship Hospital, Integrative Cardiology Zhou, Ying; China-Japan Friendship Hospital, Cardiology Jiang, Hong; China-Japan Friendship Hospital, Integrative Cardiology Li, Xianlun; China-Japan Friendship Hospital, Cardiology, Integrative Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Heart failure < CARDIOLOGY, REHABILITATION MEDICINE, Telemedicine < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Effect of Home-based Cardiac Exercise Rehabilitation with Remote
Electrocardiogram Monitoring in Patients with Chronic Heart Failure
(HERE-CHF) : Study Protocol for a Randomized Controlled Trial**

Jiahui Li^{1*}, Peng Yang^{2*}, Dongliang Fu², Xiaojun Ye¹, Lifang Zhang¹, Gang Chen³,
Yiyun Yang¹, He Luo¹, Li Chen⁴, Mingjing Shao², Chunyan Li², Yi Liu², Ying Zhou¹,
Hong Jiang^{2*}, Xianlun Li^{1,2*}

¹Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China;

²Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing
100029, China; ³Department of Rehabilitation, China-Japan Friendship Hospital,
Beijing 100029, China; ⁴Phase I Clinical Ward of Clinical Trial Research Center,
China-Japan Friendship Hospital, Beijing 100029, China.

* Jiahui Li and Peng Yang are joint first authors.

*Correspondence: Xianlun Li and Hong Jiang are both corresponding authors.

Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com.

Hong Jiang: Tel: + 86 15811227722, E-mail: drjh68@163.com.

Abstract

Introduction

Patients with chronic heart failure (CHF) can benefit from exercise rehabilitation (ER) with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Despite its reported benefits, only a limited number of patients with CHF attend ER because of poorer adherence and improper exercise may even cause adverse events. Remote electrocardiogram monitoring system (REMS) has the potential to overcome these barriers. We hypothesize that home-based cardiac ER using REMS in CHF patients is effective compared with conventional ER without monitoring.

Methods and Analysis

This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness of home-based phase-II ER with REMS in the management of CHF, which has a target enrollment of 120 patients [Left Ventricular Ejection Fraction <50%, New York Heart Association (NYHA) classes I to III]. Patients are randomized to either REMS rehabilitation group or conventional rehabilitation group in a 1:1 ratio. All the patients initiate an exercise training in a supervised setting and then transition to a home-based regimen. The supervised training phase consists of 12 supervised training sessions, 3 sessions per week for 4 weeks. During the home exercise phase, patients exercise 5 times per week, totally 8 weeks. In REMS group, patients wear monitors during exercise to ensure that exercise intensity is within the ranges set for them. REMS will also detect risky arrhythmia and give an early warning to both the patients and their doctors. The training intensity is not monitored in the conventional rehabilitation group. The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO_2 peak) (baseline vs 3 m). Secondary outcomes include 6-min Walk Test (6MWT), NYHA classes, echocardiographic parameters, cardiac biomarkers, major adverse cardiovascular events (MACE), quality of life, psychological well-being and patients' adherence to

1
2
3 the rehabilitation program.

4 5 **Ethics and Dissemination**

6
7 This study was approved by Ethics Committee of China-Japan Friendship Hospital for
8
9 Clinical Research (No. 2018-55-K39) . The results of this study will be disseminated
10
11 via peer-reviewed publications and presentations at conferences.
12

13 14 **Clinical trial registration number**

15
16 ChiCTR-RNR-17012446

17 18 **Strengths and limitations of this study**

- 19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
1. The wearable monitor used in this study is a portable cardiac monitor which can collect single-lead electrocardiogram(ECG)data for 48 hours. During the exercise, the monitor can evaluate patients' exercise intensity according to their heart rate and then remind them promptly to exercise appropriately, which may further enhance the effectiveness of ER. This monitor has been approved by Food and Drug Administration in Shandong province of China (Certificate No. Shandong Medical Device Registration Approval 20172210878).
 2. The REMS used here can detect arrhythmia and give an early warning to both the exercising patients and their doctors so as to further reduce risks. It allows patients to exercise more safely and patients are also more willing to exercise. The REMS may help improve patients' adherence to ER.
 3. Our cardiac ER program is home-based and convenient for CHF patients compared with facility-based ER. This may provide new insights in cardiac telerehabilitation in heart failure patients.
 4. The major limitation of this single-center study is the small sample size.
 5. A long-term follow-up may be also needed. Extending the exercise out to 6 months may give us better data on adherence.

54
55 **Keywords:** Cardiac exercise rehabilitation, Telerehabilitation, Chronic heart failure,
56 Remote Electrocardiogram Monitoring System

Introduction

Heart failure (HF) is a complex clinical syndrome caused by abnormal cardiac structure or function which results in impaired ventricular filling or ejection ability. It is a terminal stage of various cardiovascular diseases, which has become the global public health problem of great concern. The prevalence of HF in the whole population is approximately 1.5%-2% and 6%-10% over 65 years of age^[1]. More and more individuals are surviving an acute cardiovascular attack due to modern therapies now and the concomitant burden of chronic HF (CHF) is also increasing worldwide. At present, there are 8-10 million patients with HF in China, and the prevalence rate increases significantly with age according to China Cardiovascular report 2017^[2]. The 5-year survival rate of HF patients with clinical symptoms is 50% , similar to that of malignant tumors^[1]. Repeated visits and hospitalizations of HF patients bring heavy economic burdens to individuals, families and society.

Many HF patients on optimal cardiovascular medical therapy still suffer from dyspnea and exercise intolerance. In addition to medical treatment and device therapy, successful cardiac rehabilitation (CR) is a valuable intervention for improving aerobic fitness and overall health status in patients with HF. There is a growing consensus that exercise has a beneficial effect on patients with cardiovascular disease, even for those with severely impaired cardiac function. HF patients can benefit from proper exercise with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Exercise training is a core component of primary and secondary prevention, which has been recommended by relevant international professional associations^[3-6].

Despite its reported benefits, a limited number of HF patients attend exercise rehabilitation (ER) on a regular basis mainly because of poor patients' adherence. Furthermore, improper exercise without monitoring may even cause adverse

1
2
3 cardiovascular events such as myocardial infarction, arrhythmias and sudden death.
4 HF-A Controlled Trial Investigating Outcomes of exercise training (HF-ACTION)^[7]
5 is the largest multicenter clinical study of ER in HF, which randomly assigned 2331
6 patients to either exercise training or usual care. Only Forty-two percent of subjects in
7 their cohort completed all three of their scheduled follow-up exercise tests and 33%
8 and 25% completed two and one of their scheduled follow-up exercise tests,
9 respectively. Given the observed effect between higher adherence and improved
10 outcomes, it is more important to provide cardiac ER programs which can achieve
11 increased adherence to the exercise intervention ^[8].

12
13
14
15
16
17
18
19 Cardiac telerehabilitation using monitoring devices and remote communication with
20 patients has now been used more and more in the long-term management of
21 cardiovascular diseases outside the hospital environment. Providing objective
22 feedback data and allowing patients to track their own progress can increase patients'
23 self-management skills and thus improve their adherence. It is convenient and can
24 reduce anxiety, improve the quality of life and prognosis of patients with low medical
25 costs compared with conventional ER without monitoring ^[9-13].

26
27
28
29
30
31
32 This study is a prospective, randomized, parallel controlled clinical trial to evaluate
33 the effectiveness and safety of home-based phase-II ER under the guidance of remote
34 electrocardiogram (ECG) monitoring system (REMS) in the management of CHF
35 compared with conventional ER without monitoring. This article describes the design
36 and rationale of the **HERE-CHF** trial.

37 38 39 40 41 42 **Methods/design**

43 44 45 ***Design***

46
47 A flow chart of the study design is shown in Figure 1. The protocol is constructed and
48 presented according to the recommendations for Interventional Trials (SPIRIT) ^[14].
49 The study protocol (V1.1, 20180208) and informed consent documents (V1.1,
50 20180208) have been reviewed and approved by the Ethics Committee of
51 China-Japan Friendship Hospital for Clinical Research. If there is any amendment to
52 the protocol, approval must be sought again from the Ethics Committee. The study

1
2
3 strategy has been registered on the website of Chinese Clinical Trial Registry
4 (ChiCTR-RNR-17012446, registered on 22 August 2017), and the trial will be
5 performed in accordance with the principles of the Declaration of Helsinki and Good
6 Clinical Practice guidelines.
7
8
9

10 ***Eligibility and recruitment***

11 Patient selection criteria are listed in Table 1. Patients must have a systolic cardiac
12 dysfunction documented from a baseline echocardiogram 【LV ejection fraction (LVEF)
13 <50%】 within 6 weeks before randomization who are under stable conditions 【New
14 York Heart Association (NYHA) classes I to III】. As defined by the American College
15 of Cardiology(ACC)/American Heart Association (AHA) HF guidelines, stable
16 optimal medical therapy including β blockers, diuretics, angiotensin-converting
17 enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) and aldosterone
18 receptor antagonists for 6 weeks before enrollment is strongly advocated. If patients
19 are not treated with optimal medical therapy, then trial personnel must document the
20 underlying reason (eg, drug intolerance).
21
22
23
24
25
26
27
28
29
30
31

32 Enrollment of patients has started in April 2018. Patients will be recruited
33 consecutively from the outpatient service of Cardiology Department and Integrative
34 Cardiology Department in China-Japan Friendship Hospital by attending physicians
35 responsible for recruitment, who will obtain written consent from patients willing to
36 participate in the trial. Screening will continue until the target population is achieved.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

61 ***Sample size***

62 The target enrollment for the trial is 120 patients. A total of 500 patients with HF
63 (NYHA grade I-III) are treated in our hospital every year , which can be used as a
64 screening sample. Calculated according to the lower screening rate (50%) and the
65 designed entry criteria, the sample size that can be completed is estimated to be 100
66 patients. Referring to the previous foreign literature, the compliance of ER in 3

1
2
3 months is 70-80%. The initial screening sample size of this study is at least 120 cases,
4
5 60 cases in each group.

6 7 ***Exercise testing***

8 Prerandomization cardiopulmonary exercise testing (CPET) is used to determine
9 whether patients can exercise safely as defined by the American Association of
10 Cardiovascular and Pulmonary Rehabilitation guidelines, including checking for
11 abnormal blood pressure responses, early ischemic changes, and significant
12 arrhythmias. Exercise testing is repeated 3 month after randomization for all patients.
13
14 The primary method used for exercise testing is cycling, consistent with AHA
15 guidelines and with other trials that have assessed exercise capacity in patients with
16 HF.
17

18 19 20 21 22 23 ***Randomization and binding***

24 China-Japan Friendship Hospital clinical research data management platform is
25 commissioned to generate a random sequence of 120 numbers using SAS 9.4 software.
26
27 The random sequence will be put into sealed envelopes by staff not involved with the
28 study to avoid selecting bias. After providing informed consent and undergoing
29 baseline testing (echocardiogram and CPET), patients are randomized in a 1:1 ratio to
30 either REMS rehabilitation group or the conventional rehabilitation group according
31 to the time order of the patients' entry. Allocation concealment will be ensured and the
32 randomization code will not be released until the patient has been recruited into the
33 trial, which takes place after all baseline measurements have been completed.
34
35 Researchers involved in participants' assessments will be blinded to treatment
36 allocation.
37

38 39 40 41 42 43 44 ***Trial structure***

45 The trial structure of the study is described in the Table 2.

46 47 48 49 ***REMS***

50 Inticare-MC-06 wearable ECG monitor (Elephant Medical Electronic Technology Co. ,
51 Ltd, Jining, China), which is approved by Food and Drug Administration in Shandong
52 province of China (Certificate No. Shandong Medical Device Registration Approval
53
54
55
56

20172210878) is a medical-grade portable cardiac monitor which looks like a smaller “Band-Aid” and can collect single-lead ECG data for 48 hours. It can provide cardiac care service through a "Hardware + Software+ Cloud + Doctor" program, and support arrhythmia automatic trigger and One-Tap SOS. Inticare-MC-06 heart health monitor solution includes 5 parts: a wearable ECG monitor, mobile terminals (such as smart phones), Cardiac Healthcare Cloud Service platform of Elephant Medical (Tianjin AI-Life Medical Technology Co. , Ltd, China) , cardiologists and monitoring reports, which is technically supported by Tianjin Institute of Internet of Things Technology. The wearable ECG monitor is pasted on the chest through one-piece electrodes and transfers the ECG data to the smart phone application of cloud service platform (Elephant Heart Health) via bluetooth smart technology. If a cardiogram such as arrhythmia occurs during exercise, the system will alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and upload it in real time. The data will be transformed to the data center, while specialist will give an analysis for that report. The unique algorithm can analyze the data in real time and detect suspected arrhythmias, then give the alarm and transfer data to cloud platform for doctors to check and confirm the disease. In addition, when patients have chest discomfort, palpitation and dizziness, they can mark the ECG data through One-Tap Marking button and send the data for doctors to check and give corresponding diagnosis. At the end of the monitoring, a report will be provided.

Interventions

All the patients initiate an exercise training program following the principles of exercise prescription as recommended by the American College of Sports Medicine (ACSM) and the AHA. The exercise stage order can be warm-up, main exercise, and cool-down. For the warm-up and cool-down, walking or light stretching is recommended. The main exercise is walking. Exercise training initially begins in a supervised setting and then transitions to a home-based regimen(Table 3 and Table 4). The supervised training phase consists of 12 supervised training sessions, with a goal

1
2
3 of 3 sessions per week. Patients have up to 1 month to complete the 12 sessions
4 before transition to the home exercise phase. Patients are asked to exercise 5 times per
5 week during the home exercise phase, totally 8 weeks. Patients begin exercising at a
6 low intensity and then increase to a moderate intensity when they are able. The trial
7 protocol allows patients to walk independently.
8
9

10
11
12 In the REMS group, patients wear Inticare-MC-06 ECG monitors when exercising at
13 home to ensure that exercise intensity is within the ranges set for them and are
14 instructed on how to monitor their own exercise training at the beginning of the trial.
15
16 During the exercise, the monitor can evaluate whether patients reach the intensity and
17 time of the preset exercise prescription according to the heart rate. If the speed is not
18 enough or the intensity exceeds the preset value, the system can remind the patient
19 promptly to adjust the intensity, including speed and time course, so as to ensure the
20 patient to exercise according to the prescription. If arrhythmia occurs during exercise,
21 the system will alert the patient to stop or suspend exercise, or adjust the intensity of
22 exercise, and upload it in real time. Specialists will give an analysis report. The
23 system will give an early warning to both patients and their doctors if the arrhythmia
24 is risky. Doctors can check the data of their patients outside hospital, know about
25 their conditions and give advice in time.
26
27

28
29 The heart rate reserve (HRR) method is used to guide exercise intensity. Peak heart
30 rate is derived from a patient's most recent exercise test, and the resting heart rate is
31 taken after 5 minutes of quiet seated rest. For the first 6 supervised training sessions,
32 the training heart rate range is computed at 60% of the HRR (resting heart rate + 0.6
33 [peak heart rate-resting heart rate]). Then training intensity is increased to 70% of the
34 HRR for the rest of the supervised exercise training sessions. For the home-based
35 exercise training phase, patients are asked to perform 40 minutes of aerobic exercise.
36
37 In the REMS training arm, the training intensity should be maintained at 60% to 70%
38 of the HRR. While during the whole phase of the conventional rehabilitation arm, the
39 training intensity is not monitored.
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 ***Concomitant treatment***

55
56 Participants in both groups will continue standard therapy for HF. The medication
57
58
59
60

1
2
3 should remain unchanged during the trial, while the dosage should be adjusted in case
4 of adverse events. All procedures will be determined by physicians following the
5 clinical guidelines.
6
7

8 ***Adherence***

9
10 During the training phase, participants will be asked to exercise strictly according to
11 the prescription and record each exercise process with designed cards. Investigators
12 will make telephone reminders before each visit and then give face-to-face reminders
13 at each study visit emphasizing the importance of adherence. Compliance of ER in
14 subjects are expressed in rate.
15
16
17
18

19 ***Outcome assessments***

20
21 The primary outcome is exercise capacity improvement measured by peak oxygen
22 uptake (VO₂ peak) (baseline vs 3 m). The secondary outcomes are: (1) difference in
23 the meters walked in the 6-min Walk Test (6MWT); (2) improvement in heart
24 function assessed by NYHA classifications; (3) improvement in echocardiographic
25 parameters of systolic and diastolic function; (4) changes in biomarkers, including
26 brain natriuretic peptide (BNP) / N-terminal-pro-brain natriuretic peptide
27 (NT-pro-BNP) and Troponin-T/I; (5) changes in major adverse cardiovascular events
28 (MACE) including worsening HF event, HF hospitalization, myocardial infarction,
29 stroke, revascularization and cardiovascular mortality; (6) qualitative evaluation of
30 patients' adherence to the rehabilitation program. The investigators will also use
31 several validated psychometric instruments to measure health-related quality of life
32 and depression. These measurements include HF Symptom Scale , Minnesota Living
33 with Heart Failure Questionnaire (MLHFQ), 36-Item Short Form Health Survey
34 (SF-36), Beck Depression Inventory-II (BDI-II) and General Self-Efficacy Scale
35 (GSE). Researchers involved in participants' assessments will be blinded to treatment
36 allocation.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 ***Withdrawal***

53
54 According to Ethics Committee of China-Japan Friendship Hospital for Clinical
55 Research legislations, we inform the patients about their rights as subjects in a
56
57
58

1
2
3 scientific trial and about their discontinuation rights. We do this to make patients
4 consider participation thoroughly to diminish the likelihood of their dropping out.
5
6 Patients can withdraw from the trial at their own request or at the request of their legal
7
8 representative at any time.
9

10 ***Data collection, management, and analysis***

11 All patients' data will be recorded by trained clinical researchers using a standardized
12 case report form (CRF). Original data should be recorded timely and accurately.
13
14 Laboratory reports copies should also be kept. All CRFs will be stored in locked file
15
16 cabinets in areas with limited access. All laboratory specimens will be identified by a
17
18 coded number to maintain participant confidentiality. Data managers from Beijing
19
20 Cardiar Technology, China are responsible for the data entry and management. The
21
22 database is established by PHP language under Linux system. Two data managers
23
24 perform double entry independently and proofread to ensure the data accuracy.
25
26 China-Japan Friendship Hospital clinical research data management platform is
27
28 responsible for data monitoring, which is independent of the study organizers. All
29
30 individuals involved in data management and analysis will be blinded to treatment
31
32 allocation. Principal investigators will have direct access to data sets. Data dispersed
33
34 to project team members will be blinded of any identifying participant information.
35

36 ***Adverse events monitoring***

37 All adverse events that occurred during the 3-month study period will be reported in
38
39 the final paper. A serious adverse event is defined as any untoward medical
40
41 occurrence resulting in hospitalization or which results in a life-threatening problem,
42
43 death, or disability. Adverse events will be defined as any untoward occurrences in
44
45 study participants, potentially related to implementation of the study protocol. All
46
47 serious and unexpected adverse events will be reported to the Ethics Committee as
48
49 required.
50

51 ***Statistical analysis***

52 Continuous variables will be presented as the mean \pm standard deviation (SD), median
53
54 or interquartile range (IQR). Baseline characteristics of the cohort will be summarized
55
56 using descriptive statistics. Whether imbalances exist will be analyzed between
57

1
2
3 groups. Comparison of numerical variables between the two groups is made using
4 Student's t-test for independent samples when normally distributed. Categorical
5 variables will be described as frequencies and percentages and compared using χ^2 test.
6
7 Mann-Whitney U test will be used if data are not normally distributed.
8

9
10 Analysis of outcomes will be conducted according to the intention-to-treat (ITT)
11 principle. We will use three analysis sets: full analysis set (FAS), per protocol set (PPS)
12 and safety set. The FAS includes all patients randomized, and the PPS consists of all
13 patients who complete the treatment protocol. The safety set consists of patients who
14 receive at least one treatment with safety records after randomization. Dropouts will
15 be included in the analysis by modern imputation methods for missing data.
16
17

18 All statistical tests will be 2-tailed. $P < 0.05$ is considered statistically significant. All
19 statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd
20 using SAS 9.4 software.
21

22 ***Patient and Public Involvement (PPI)***

23
24 During the study design, CHF patients and their relatives were invited to participate in
25 surveys and discussions, which allowed us to know their strong desire in ER,
26 especially home-based telerehabilitation. We also selected several patients to use the
27 monitor, which helped us to identify the problems in application. Besides, we invited
28 medical specialists including cardiologists, rehabilitation therapists and statistical
29 analysts to discuss the study design and revise the intervention method and outcome
30 measures. The results of our study will be disseminated to PPI representatives and
31 study participants who wish to be notified.
32
33
34
35
36
37
38
39
40
41
42
43

44 **Discussion**

45
46 **HERE-CHF** evaluates the effect of a cardiac telerehabilitation intervention that
47 combines modern technology (sensor technology, internet and remote consultation)
48 with evidence-based ER guidance strategies including prevention of adverse events
49 when exercising. The objective of this study is to investigate whether home-based
50 cardiac ER using REMS is superior to conventional ER without monitoring in CHF
51 patients. We hypothesize that this intervention will result in improved physical
52
53
54
55
56
57

1
2
3 activity levels and better quality of life.

4 Home-based CR is a method to improve participation rate of ER in HF patients.
5
6 Whether exercise prescription can be efficiently performed and the safety in exercise
7
8 are two main issues in home-based ER. While exercise intensity is the key of exercise
9
10 prescription because the exercise has to be appropriate. Heart rate is the most
11
12 important factor to monitor the patient's exercise intensity. Our wearable ECG
13
14 monitor can evaluate whether patients reach the intensity according to the heart rate
15
16 and remind the patients in time so as to ensure that exercise intensity is within the
17
18 preset range. REMS will also detect risky arrhythmia and give an early warning to
19
20 both the patients and their doctors, which can encourage patients to overcome fear and
21
22 adhere to exercise. The use of our REMS offers a prospect for the delivery and
23
24 expansion of home-based cardiac ER programs in HF patients beyond the supervised
25
26 setting and will help to increase adherence, reduce risk factors and improve
27
28 benefit-cost ratio , which may further enhance the effectiveness of ER.

29 CPET is useful to evaluate patient exercise capacity and exertional symptoms and can
30
31 offer numerous physiologic parameters. Multiple CPET-derived variables have been
32
33 assessed for their association with mortality in systolic HF patients and peak VO_2 is
34
35 shown to be the strongest predictor of mortality ^[15]. Therefore we select it as the
36
37 primary outcome in **HERE-CHF**. The choice of the 6MWT as a secondary outcome
38
39 is due to its useful prognostic information similar to peak VO_2 ^[16]. 6MWT is less
40
41 expensive and much more convenient in comparison to the nontrivial costs of CPET
42
43 with its distinctive value as a measure of routine activity. Quality of life and
44
45 psychological state are important in the evaluation of home-based ER, which are also
46
47 included in our study.

48 **Conclusion**

49
50 The **HERE-CHF** study will provide new insights in the effect of home-based cardiac
51
52 ER guided by REMS. Our REMS will help to increase HF patients' adherence and
53
54 reduce risk factors, which may further enhance the effectiveness of ER.
55
56
57

Acknowledgements

The authors thank all the patients advisers and medical students for their assistance in the study.

Contributors

Xianlun Li, Hong Jiang, Jiahui Li and Peng Yang conceived the original concept of the study, registered the trial and wrote the draft of the protocol manuscript.

Dongliang Fu, Xiaojun Ye, Lifang Zhang, Gang Chen, Yiyun Yang, He Luo, Li Chen , Mingjing Shao , Chunyan Li, Yi Liu and Ying Zhou contributed to the design of the study. All the authors read and discussed the manuscript, and approved the final version.

Funding

This work is financially supported by China Capital Health Development Research Special Fund (2018-2-4064). Inticare-MC-06 ECG monitors are provided by Tianjin AI-Life Medical Technology Co. , Ltd, China. The funding source does not influence or comment on planned methods, protocol, data analysis, or the draft report.

Competing interests

The authors declare that they have no competing interests.

References

1. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2007 Dec; 35(12):1076-95.
2. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, Wu ZS, Li HJ, Gu DF, Yang YJ, Zheng Z, Jiang LX, Hu SS Representative group of Chinese cardiovascular diseases report. Report on cardiovascular diseases in China (2017). *Chinese Circulation Journal*. 2018; 33(1):1-7.

- 1
2
3 3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC,
4 Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA,
5 McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW,
6 Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation;
7 American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA
8 guideline for the management of heart failure: a report of the American College of
9 Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
10 J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.
11
- 12 4. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of
13 Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of
14 heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Feb;42(2):98-122.
15
- 16 5. Chinese Rehabilitation Medical Association Professional Committee of Cardiovascular
17 Diseases; Committee of Cardio-Cerebral-Vascular Diseases of GSC. Chinese expert
18 consensus on cardiac rehabilitation for patients with chronic stable heart failure.
19 Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Sep;42(9):714-20.
20
- 21 6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
22 González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
23 Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
24 Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document
25 Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic
26 heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart
27 failure of the European Society of Cardiology (ESC). Developed with the special
28 contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016
29 Aug;18(8):891-975.
30
- 31 7. Keteyian SJ, Isaac D, Thadani U, Roy BA, Bensimhon DR, McKelvie R, Russell SD,
32 Hellkamp AS, Kraus WE; HF-ACTION Investigators. Safety of symptom-limited
33 cardiopulmonary exercise testing in patients with chronic heart failure due to severe left
34 ventricular systolic dysfunction. Am Heart J. 2009 Oct;158(4 Suppl):S72-7.
35
- 36 8. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training
37 Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Rehabilitation: A Systematic Review and Meta-regression. *Sports Med Open*. 2017 Dec;
4 3(1):19.
5
6
7 9. Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative
8 models of cardiac rehabilitation: a systematic review[J]. *Eur J Prev Cardiol*. 2015 Jan;
9 22(1):35-74.
10
11
12 10. Lee Y, Lee J, Seo H, Kim K, Min D, Lee J, Choi J. Effects of Home-based Exercise
13 Training with Wireless Monitoring on the Left Ventricular Function of Acute Coronary
14 Syndrome Patients. *J Phys Ther Sci*. 2013 May;25(5):631-3.
15
16
17 11. Chung H, Ko H, Thap T, Jeong C, Noh SE, Yoon KH, Lee J. Smartphone-Based
18 Cardiac Rehabilitation Program: Feasibility Study. *PLoS One*. 2016 Aug
19 23;11(8):e0161268.
20
21
22 12. Hwang R, Bruning J, Morris NR, Mandrusiak A, Russell T. Home-based
23 telerehabilitation is not inferior to a centre-based program in patients with chronic heart
24 failure: a randomised trial. *J Physiother*. 2017 Apr;63(2):101-107.
25
26
27 13. Di Lenarda A, Casolo G, Gulizia MM, Aspromonte N, Scalvini S, Mortara A, Alunni G,
28 Ricci RP, Mantovan R, Russo G, Gensini GF, Romeo F. The future of telemedicine for
29 the management of heart failure patients: a Consensus Document of the Italian
30 Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology
31 (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). *Eur Heart*
32 *J Suppl*. 2017 May;19(Suppl D):D113-D129.
33
34
35 14. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new
36 guidance for content of clinical trial protocols. *Lancet*. 2013; 381(9861):91-2.
37
38
39 15. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, Leifer ES, Fleg
40 JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, O'Connor CM, Ehrman JK,
41 Walsh MN, Ewald G, Bensimhon D, Russell SD; HF-ACTION Investigators. Variables
42 Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in
43 Chronic Systolic Heart Failure. *J Am Coll Cardiol*. 2016 Feb 23;67(7):780-9.
44
45
46 16. Daniel E. Forman, Jerome L. Fleg, Dalane Kitzman, Clinton A. Brawner, Ann Swank,
47 Robert McKelvie, Robert Clare, Stephen J. Ellis, Mark E. Dunlap, Vera Bittner. 6
48 Minute Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary
49
50
51
52
53
54
55
56
57
58
59
60

Exercise Testing in Ambulatory Outpatients with Systolic Heart Failure. J Am Coll
Cardiol. 2012 Dec 25; 60(25): 2653–2661.

Table 1. HERE-CHF trial inclusion and exclusion criteria

Inclusion criteria

1. Aged 18-75 years old;
2. NYHA I-III; LVEF < 50% in 6 weeks before randomization;
3. in stable condition after heart failure standard drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device), no fluid retention, constant weight;
4. able to perform exercise rehabilitation;
5. clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

1. exercise rehabilitation can not be carried out due to physical disability and contraindication;
 2. with a contraindication to cardiopulmonary exercise test;
 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid artery or other major vascular surgery; percutaneous coronary intervention (PCI) or carotid artery angioplasty; sustained ventricular tachycardia or fibrillation;
 4. coronary revascularization or heart transplantation is planned;
 5. persistent atrial arrhythmias ; ventricular arrhythmias were not effectively controlled (using
-

-
- 1
2
3 an antiarrhythmic drug or an implantable defibrillator);
4 6. uncorrected primary obstructive or severe regurgitant heart valve disease, restrictive or
5 hypertrophic cardiomyopathy;
6 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker
7 implantation; need implantable device therapy for heart failure;
8 8. obstructive or bronchospasm lung disease(such as asthma, bronchitis, etc) needing oral or
9 inhaled bronchodilator or glucocorticoids therapy;
10 9. pregnant or lactating women and those planning to conceive during the trial;
11 10. cancer or other systemic diseases with an expected survival of less than 12 months;
12 11. other clinical trial drugs were taken or in other medical device trial within 30 days before
13 admission;
14 12. unable to participate in this study after the clinical evaluation by investigators.
-

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 2 Trial structure of the study

Time Assessment	Screening (-14~-1d)	Exercise Rehabilitation in Clinic			Exercise Rehabilitation at Home	
		T0 Visit 1 Baseline	T1 Visit 2 2 nd weekend	T2 Visit 3 4 th weekend	T3 Visit 4 8 th weekend	T4 Visit 5 12 th weekend
medical history	√					
Inclusion/Exclusion Form	√					
Consent Form	√					
Comorbidity	√	√	√	√	√	√
Concomitant medication	√	√	√	√	√	√
Physical examination	√	√	√	√	√	√
Troponin T/I		√				√
BNP/NT-proBNP		√				√
Electrocardiogram	√	√		√	√	√
Holter	√					√
NYHA classification	√	√		√	√	√
Echocardiography	√	√				√
CPET	√					√
6MWT		√				√
Heart failure symptom scale		√				√

MLHFQ		√				√
SF-36		√				√
BDI-II		√				√
GSE		√				√
Compliance				√	√	√
Adverse event			√	√	√	√
Monitor and APP training		√				

The time window for each visit is $\pm 3d$. MLHFQ: Minnesota Living with Heart Failure Questionnaire. SF-36: 36-Item Short Form Health Survey. BDI-II: Beck Depression Inventory. GSE: General Self-Efficacy Scale.

Table 3. Exercise training program in remote ECG monitoring system rehabilitation group

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	2	3	15-30	60	walk
supervised by Rehabilitation specialist	Clinic	2	3	15-30	70	walk
Supervised by remote ECG monitoring	home	8	5	40	60-70	walk

Table 4. Exercise training program in conventional rehabilitation group without monitoring

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	4	3	15-30	without monitoring	walk
Symptom-Limited, self-adaption	home	8	5	40	without monitoring	walk

Legends

Figure 1 Study flow chart. CPET: cardiopulmonary exercise testing. 6MWT: 6-min Walk Test. REMS : remote electrocardiogram monitoring system.

For peer review only




Figure 1 Study flow chart. CPET: cardiopulmonary exercise testing. 6MWT: 6-min Walk Test. REMS : remote electrocardiogram monitoring system.

90x90mm (300 x 300 DPI)

SPIRIT 2013 checklist

Section/item	ItemNo	Information
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym page 1 Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure (HERE-CHF) : Study Protocol for a Randomized Controlled Trial page 1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry page 3 www.chictr.org.cn ChiCTR-RNR-17012446
	2b	All items from the World Health Organization Trial Registration Data Set N/A Registration number : ChiCTR-RNR-17012446 Date of Last Refreshed on : 2017/8/22 10:09:47 Registration Status : 1008001 Prospective registration Public title : An Exploratory Clinical Study on Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		Failure	
	Scientific title :	An Exploratory Clinical Study on Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure	
	Applicant :	Li Jiahui	Study leader : Li Xianlun
	Applicant telephone :	+86 13436354344	Study leader's telephone : +86 13910812495
	Applicant E-mail :	veighlee@163.com	Study leader's E-mail : leexianlun@163.com
	Applicant address :	2 Yinghua Street East, Chaoyang District, Beijing, China , 100029	Study leader's address : 2 Yinghua Street East, Chaoyang District, Beijing, China ,100029
	Applicant's institution : China-Japan Friendship Hospital		

	<p>Primary sponsor : China-Japan Friendship Hospital</p> <p>Primary sponsor's address : 2 Yinghua Street East, Chaoyang District, Beijing, China</p> <p>Source(s) of funding : Self-financing</p> <p>Target disease : heart failure</p> <p>Study type : Relative factors research</p> <p>Study phase : New Treatment Measure Clinical Study</p> <p>Objectives of Study :</p> <p>To evaluate the efficacy and safety of home-based cardiac exercise rehabilitation with remote electrocardiogram(ECG) monitoring in patients with chronic heart failure(NYHA classification I-III).To demonstrate that home-based exercise rehabilitation with remote ECG monitoring has the advantages of standardization and easy implementation compared with traditional exercise rehabilitation.</p> <p>Study design :</p> <p>Randomized parallel controlled trial</p> <p>Inclusion criteria</p> <p>(1) Aged 18-75 years old, male or female; (2) chronic heart failure (NYHA classification I-III); LVEF<50% in 6 weeks before randomization; (3) in stable condition after heart failure standard</p>
--	--

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device),no fluid retention,constant weight; (4) able to perform exercise rehabilitation; (5) clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.</p> <p>Exclusion criteria :</p> <ol style="list-style-type: none"> 1. exercise rehabilitation can not be carried out due to physical disability and contraindication; 2. with a contraindication to cardiopulmonary exercise test; 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack;cardiac,carotid artery or other major vascular surgery;percutaneous coronary intervention (PCI)or carotid artery angioplasty;sustained ventricular tachycardia or fibrillation; 4. coronary revascularization or heart transplantation is planned; 5. ventricular arrhythmias were not effectively controlled (using an antiarrhythmic drug or an implantable defibrillator); 6. uncorrected primary obstructive or severe regurgitant heart valve disease,restrictive or hypertrophic cardiomyopathy; 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker implantation; need implantable device therapy for heart failure; 8. obstructive or bronchospasm lung disease(such as asthma, bronchitis,etc) needing oral or inhaled bronchodilator or glucocorticoids therapy; 9. pregnant or lactating women and those planning to conceive during the trial; 10. cancer or other systemic diseases with an expected survival of less than 12 months; 11. other clinical trial drugs were taken or in other medical device trial within 30 days before admission; 12. unable to participate in this study after the clinical evaluation by
--	--

	<p>investigators.</p> <p>Study execute time : From2018/01/01 To 2020/12/31</p> <p>Interventions :</p> <p>Remote electrocardiogram monitoring group Sample size : 60</p> <p>Control group without monitoring Sample size : 60</p> <p>Countries of recruitment and research settings : China-Japan Friendship Hospital,China</p> <p>Level of the institution : Tertiary A hospital</p> <p>Outcomes : VO2Peak , 6 minute walk distance , left ventricular ejection fraction, blood test</p> <p>Randomization Procedure (please state who generates the random number sequence and by what method) :</p> <p>The clinical data management platform of China-Japan Friendship Hospital is commissioned to create SAS 9.4 software to generate random concealment table tables. Masked envelopes will be produced by random concealment and participants are admitted by 1:1 random principle.</p> <p>The time of sharing IPD : Within six months after the trial complete</p> <p>The way of sharing IPD" (include metadata and protocol, If use web-based public database, please</p>
--	---

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		provide the url) : Publish original data by June 2021 in the form of meetings, speeches or articles.
Protocol version	3	Date and version identifier page 5 20180208 V1.1
Funding	4	Sources and types of financial, material, and other support page 13 This work is financially supported by China Capital Health Development Research Special Fund (2018-2-4064) . Inticare-MC-06 ECG monitors are provided by Tianjin AI-Life Medical Technology Co. , Ltd, China. The funding source does not influence or comment on planned methods, protocol, data analysis, or the draft report.
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors page1, 13 Jiahui Li1*, Peng Yang2*, Dongliang Fu2, Xiaojun Ye1, Lifang Zhang1, Gang Chen3, Yiyun Yang1, He Luo1, Li Chen4 , Mingjing Shao2 , Chunyan Li2, Yi Liu2 , Ying Zhou1, Hong Jiang2 ✧, Xianlun Li1,2✧ 1Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China; 2Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing 100029, China; 3Department of Rehabilitation, China-Japan Friendship Hospital, Beijing 100029, China; 4Phase I Clinical Ward of Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing 100029, China.

		<p>✘ Correspondence: Xianlun Li and Hong Jiang are both corresponding authors.</p> <p>Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com. Hong Jiang: Tel: + 86 15811227722, E-mail: drjh68@163.com.</p> <p>Xianlun Li, Hong Jiang, Jiahui Li and Peng Yang conceived the original concept of the study and wrote the draft of the protocol manuscript. Other authors contributed to the design of the study. All authors approved the final manuscript.</p>
	5b	<p>Name and contact information for the trial sponsor page 1</p> <p>Trial sponsor: Beijing Municipal Commission of Health and Family Planning Telephone: 86-10-83970661 Principal investigator: Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com.</p>
	5c	<p>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities page 13</p> <p>The funding source does not influence or comment on planned methods, protocol, data analysis, or the draft report.</p>
	5d	<p>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) page 6,7,10-11,</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to generate a random sequence of 120 numbers using SAS 9.4 software. The random sequence will be put into sealed envelopes by staff not involved with the study to avoid selecting bias.</p> <p>Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organisers.</p> <p>All statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd using SAS 9.4 software.</p>
Introduction		
Background and rationale	6a	<p>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention Page 4,5</p> <p>Heart failure (HF) is a complex clinical syndrome caused by abnormal cardiac structure or function which results in impaired ventricular filling or ejection ability. It is a terminal stage of</p>

1
2
3
4
5 various cardiovascular diseases, which has become the global public health problem of great
6 concern. The prevalence of HF in the whole population is approximately 1.5%-2% and 6%-10%
7 over 65 years of age [1]. More and more individuals are surviving an acute cardiovascular attack
8 due to modern therapies now and the concomitant burden of chronic HF (CHF) is also increasing
9 worldwide. At present, there are 8-10 million patients with HF in China, and the prevalence rate
10 increases significantly with age according to China Cardiovascular report 2017[2]. The 5-year
11 survival rate of HF patients with clinical symptoms is 50% ,similar to that of malignant tumors[1].
12 Repeated visits and hospitalizations of HF patients bring heavy economic burdens to individuals,
13 families and society.
14
15 Many HF patients on optimal cardiovascular medical therapy still suffer from dyspnea and
16 exercise intolerance. In addition to medical treatment and device therapy, successful cardiac
17 rehabilitation (CR) is a valuable intervention for improving aerobic fitness and overall health
18 status in patients with HF. There is a growing consensus that exercise has a beneficial effect on
19 patients with cardiovascular disease, even for those with severely impaired cardiac function. HF
20 patients can benefit from proper exercise with significant improvements in exercise capacity,
21 quality of life, and reduction in hospitalizations. Exercise training is a core component of primary
22 and secondary prevention, which has been recommended by relevant international professional
23 associations[3-6].
24
25 Despite its reported benefits, a limited number of HF patients attend exercise rehabilitation (ER)
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>on a regular basis mainly because of poor patients' adherence. Furthermore, improper exercise without monitoring may even cause adverse cardiovascular events such as myocardial infarction, arrhythmias and sudden death. HF-A Controlled Trial Investigating Outcomes of exercise training (HF-ACTION)[7] is the largest multicenter clinical study of ER in HF, which randomly assigned 2331 patients to either exercise training or usual care. Only Forty-two percent of subjects in their cohort completed all three of their scheduled follow-up exercise tests and 33% and 25% completed two and one of their scheduled follow-up exercise tests, respectively. Given the observed effect between higher adherence and improved outcomes, it is more important to provide cardiac ER programs which can achieve increased adherence to the exercise intervention [8].</p> <p>Cardiac telerehabilitation using monitoring devices and remote communication with patients has now been used more and more in the long-term management of cardiovascular diseases outside the hospital environment. Providing objective feedback data and allowing patients to track their own progress can increase patients' self-management skills and thus improve their adherence. It is convenient and can reduce anxiety, improve the quality of life and prognosis of patients with low medical costs compared with conventional ER without monitoring [9-13].</p>
	6b	<p>Explanation for choice of comparators page 5</p> <p>Cardiac telerehabilitation using monitoring devices and remote communication with patients has now been used more and more in the long-term management of cardiovascular diseases outside</p>

		the hospital environment. Providing objective feedback data and allowing patients to track their own progress can increase patients' self-management skills and thus improve their adherence. It is convenient and can reduce anxiety, improve the quality of life and prognosis of patients with low medical costs compared with conventional ER without monitoring [9-13].
Objectives	7	Specific objectives or hypotheses page 5 This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness and safety of home-based phase-II ER under the guidance of remote electrocardiogram (ECG) monitoring system (REMS) in the management of CHF compared with conventional ER without monitoring.
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) Page 5 This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness and safety of home-based phase-II ER under the guidance of remote electrocardiogram (ECG) monitoring system (REMS) in the management of CHF compared with conventional ER without monitoring.
Methods: Participants, interventions, and outcomes		
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained page 6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment.</p>
Eligibility criteria	10	<p>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) Page 6,17</p> <p>Inclusion criteria: 1. Aged 18-75 years old; 2. NYHA I-III; LVEF<50% in 6 weeks before randomization; 3. in stable condition after heart failure standard drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device), no fluid retention, constant weight; 4. able to perform exercise rehabilitation; 5. clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.</p> <p>Exclusion criteria : 1. exercise rehabilitation can not be carried out due to physical disability and contraindication; 2. with a contraindication to cardiopulmonary exercise test; 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid artery or other major vascular surgery; percutaneous coronary intervention (PCI)or carotid artery angioplasty; sustained ventricular tachycardia or fibrillation; 4. coronary</p>

		<p>revascularization or heart transplantation is planned; 5. persistent atrial arrhythmias ; ventricular arrhythmias were not effectively controlled (using an antiarrhythmic drug or an implantable defibrillator); 6. uncorrected primary obstructive or severe regurgitant heart valve disease, restrictive or hypertrophic cardiomyopathy; 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker implantation; need implantable device therapy for heart failure; 8. obstructive or bronchospasm lung disease(such as asthma, bronchitis, etc) needing oral or inhaled bronchodilator or glucocorticoids therapy; 9. pregnant or lactating women and those planning to conceive during the trial; 10. cancer or other systemic diseases with an expected survival of less than 12 months; 11. other clinical trial drugs were taken or in other medical device trial within 30 days before admission; 12. unable to participate in this study after the clinical evaluation by investigators</p>
Interventions	11a	<p>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered page8,9</p> <p>All the patients initiate an exercise training program following the principles of exercise prescription as recommended by the American College of Sports Medicine (ACSM) and the AHA. The exercise stage order can be warm-up, main exercise, and cool-down. For the warm-up and cool-down, walking or light stretching is recommended. The main exercise is walking. Exercise training initially begins in a supervised setting and then transitions to a home-based</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>regimen (Table 3 and Table 4) . The supervised training phase consists of 12 supervised training sessions, with a goal of 3 sessions per week. Patients have up to 1 month to complete the 12 sessions before transition to the home exercise phase. Patients are asked to exercise 5 times per week during the home exercise phase, totally 8 weeks. Patients begin exercising at a low intensity and then increase to a moderate intensity when they are able. The trial protocol allows patients to walk independently.</p> <p>In the REMS group, patients wear Inticare-MC-06 ECG monitors when exercising at home to ensure that exercise intensity is within the ranges set for them and are instructed on how to monitor their own exercise training at the beginning of the trial. During the exercise, the monitor can evaluate whether patients reach the intensity and time of the preset exercise prescription according to the heart rate. If the speed is not enough or the intensity exceeds the preset value, the system can remind the patient promptly to adjust the intensity, including speed and time course, so as to ensure the patient to exercise according to the prescription. If arrhythmia occurs during exercise, the system will alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and upload it in real time. Specialists will give an analysis report. The system will give an early warning to both patients and their doctors if the arrhythmia is risky. Doctors can check the data of their patients outside hospital, know about their conditions and give advice in time.</p> <p>The heart rate reserve (HRR) method is used to guide exercise intensity. Peak heart rate is derived from a patient’s most recent exercise test, and the resting heart rate is taken after 5 minutes of quiet seated rest. For the first 6 supervised training sessions, the training heart rate range is</p>
--	---

		<p>computed at 60% of the HRR (resting heart rate + 0.6 [peak heart rate-resting heart rate]). Then training intensity is increased to 70% of the HRR for the rest of the supervised exercise training sessions. For the home-based exercise training phase, patients are asked to perform 40 minutes of aerobic exercise. In the REMS training arm, the training intensity should be maintained at 60% to 70% of the HRR. While during the whole phase of the conventional rehabilitation arm, the training intensity is not monitored.</p>
	11b	<p>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</p> <p>Page 8</p> <p>If a cardiogram such as arrhythmia occurs during exercise, the system will alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and upload it in real time. The data will be transformed to the data center, while specialist will give an analysis for that report. The unique algorithm can analyze the data in real time and detect suspected arrhythmias, then give the alarm and transfer data to cloud platform for doctors to check and confirm the disease. In addition, when patients have chest discomfort, palpitation and dizziness, they can mark the ECG data through One-Tap Marking button and send the data for doctors to check and give corresponding diagnosis. At the end of the monitoring, a report will be provided.</p>
	11c	<p>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Page 9,10</p> <p>During the training phase, participants will be asked to exercise strictly according to the prescription and record each exercise process with designed cards. Investigators will make telephone reminders before each visit and then give face-to-face reminders at each study visit emphasizing the importance of adherence. Compliance of ER in subjects are expressed in rate.</p>
	11d	<p>Relevant concomitant care and interventions that are permitted or prohibited during the trial</p> <p>Page 9</p> <p>Participants in both groups will continue standard therapy for HF. The medication should remain unchanged during the trial, while the dosage should be adjusted in case of adverse events. All procedures will be determined by physicians following the clinical guidelines.</p>
Outcomes	12	<p>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</p> <p>Page 10</p> <p>The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO2 peak) (baseline vs 3 m). The secondary outcomes are: (1) difference in the meters walked in the 6-min Walk Test (6MWT); (2) improvement in heart function assessed by NYHA classifications; (3) improvement in echocardiographic parameters of systolic and diastolic function; (4) changes in biomarkers, including brain natriuretic peptide (BNP) / N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and Troponin-T/I; (5) changes in major adverse cardiovascular events (MACE) including worsening HF event, HF hospitalization, myocardial infarction, stroke, revascularization and cardiovascular mortality; (6) qualitative evaluation of patients' adherence to the rehabilitation program. The investigators will also use several validated psychometric instruments to measure health-related quality of life and depression. These measurements include</p>

		<p>HF Symptom Scale, Minnesota Living with Heart Failure Questionnaire (MLHFQ), 36-Item Short Form Health Survey (SF-36), Beck Depression Inventory-II (BDI-II) and General Self-Efficacy Scale (GSE).</p>
<p>Participant timeline</p>	<p>13</p>	<p>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended Figure 1</p> <pre> graph TD A[Patients with criteria] --> B[Patients sign informed consent] B --> C[Baseline CPET+6MWT] C --> D[1:1 Randomization (n=120)] D --> E[Remote monitoring rehabilitation group (n=60)] D --> F[Conventional rehabilitation group (n=60)] E --> G[Exercise training by REMS +standard therapy (3m)] F --> H[Exercise training without Monitoring +standard therapy (3m)] G --> I[Safety and effectiveness evaluation] H --> I </pre>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Sample size	14	<p>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations Page 6</p> <p>The target enrollment for the trial is 120 patients. A total of 500 patients with HF (NYHA grade I-III) are treated in our hospital every year, which can be used as a screening sample. Calculated according to the lower screening rate (50%) and the designed entry criteria, the sample size that can be completed is estimated to be 100 patients. Referring to the previous foreign literature, the compliance of ER in 3 months is 70-80%. The initial screening sample size of this study is at least 120 cases, 60 cases in each group.</p>
Recruitment	15	<p>Strategies for achieving adequate participant enrolment to reach target sample size Page 6</p> <p>Screening will continue until the target population is achieved. A recruitment advertisement has also been utilized in our hospital.</p>
Methods: Assignment of interventions (for controlled trials)		
Allocation:		
Sequence generation	16a	<p>Method of generating the allocation sequence (eg, computer-generated random numbers) and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enroll participants or assign interventions</p> <p>Page 7</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to</p>

		generate a random sequence of 120 numbers using SAS 9.4 software. The random sequence will be put into sealed envelopes by staff not involved with the study to avoid selecting bias.
Allocation concealment mechanism	16b	<p>Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned Page 7</p> <p>After providing informed consent and undergoing baseline testing (echocardiogram and CPET), patients are randomized in a 1:1 ratio to either REMS rehabilitation group or the conventional rehabilitation group according to the time order of the patients' entry. Allocation concealment will be ensured and the randomization code will not be released until the patient has been recruited into the trial, which takes place after all baseline measurements have been completed. Researchers involved in participants' assessments will be blinded to treatment allocation.</p>
Implementation	16c	<p>Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions Page 6,7</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to generate a random sequence of 120 numbers using SAS 9.4 software.</p> <p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p>
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts) and how

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		Page 10,11 Researchers involved in participants’ assessments will be blinded to treatment allocation. All individuals involved in data management and analysis will be blinded to treatment allocation.
	17b	If blinded, circumstances under which unblinding is permissible and procedure for revealing a participant’s allocated intervention during the trial
		N/A
Methods: Data collection, management, and analysis		
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Page10,11 All patients’ data will be recorded by trained clinical researchers using a standardized case report form (CRF). Original data should be recorded timely and accurately. Laboratory reports copies should also be kept. All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality. Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers. All individuals involved in data management and analysis will be blinded to treatment allocation. Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

		<p>Page 9,10</p> <p>During the training phase, participants will be asked to exercise strictly according to the prescription and record each exercise process with designed cards. Investigators will make telephone reminders before each visit and then give face-to-face reminders at each study visit emphasizing the importance of adherence.</p>
Data management	19	<p>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol</p> <p>Page10,11</p> <p>All patients' data will be recorded by trained clinical researchers using a standardized case report form (CRF). Original data should be recorded timely and accurately. Laboratory reports copies should also be kept. All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality. Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. The database is established by PHP language under Linux system. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers. All individuals involved in data management and analysis will be blinded to treatment allocation. Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.</p>
Statistical methods	20a	<p>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol</p> <p>Page 11,12</p> <p>Continuous variables will be presented as the mean \pmstandard deviation (SD), median or interquartile range (IQR). Baseline characteristics of the cohort will be summarized using</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>descriptive statistics. Whether imbalances exist will be analyzed between groups. Comparison of numerical variables between the two groups is made using Student’s t-test for independent samples when normally distributed. Categorical variables will be described as frequencies and percentages and compared using χ^2 test. Mann-Whitney U test will be used if data are not normally distributed.</p> <p>Analysis of outcomes will be conducted according to the intention-to-treat (ITT) principle. We will use three analysis sets: full analysis set (FAS), per protocol set (PPS) and safety set. The FAS includes all patients randomized, and the PPS consists of all patients who complete the treatment protocol. The safety set consists of patients who receive at least one treatment with safety records after randomization. Dropouts will be included in the analysis by modern imputation methods for missing data.</p> <p>All statistical tests will be 2-tailed. $P < 0.05$ is considered statistically significant. All statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd using SAS 9.4 software.</p>
	20b	<p>Methods for any additional analyses (eg, subgroup and adjusted analyses) page 12</p> <p>Dropouts will be included in the analysis by modern imputation methods for missing data.</p>
	20c	<p>Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</p> <p>Page 11,12</p> <p>Analysis of outcomes will be conducted according to the intention-to-treat (ITT) principle. We will use three analysis sets: full analysis set (FAS), per protocol set (PPS) and safety set. The FAS includes all patients randomized, and the PPS consists of all patients who complete the treatment protocol. The safety set consists of patients who receive at least one treatment with safety records after randomization.</p>
Methods: Monitoring		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure;

		<p>statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</p> <p>Page11</p> <p>China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers.</p>
	21b	<p>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</p> <p>N/A</p>
Harms	22	<p>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</p> <p>Page 11</p> <p>All adverse events that occurred during the 3-month study period will be reported in the final paper. A serious adverse event is defined as any untoward medical occurrence resulting in hospitalization or which results in a life-threatening problem, death, or disability. Adverse events will be defined as any untoward occurrences in study participants, potentially related to implementation of the study protocol. All serious and unexpected adverse events will be reported to the Ethics Committee as required.</p>
Auditing	23	<p>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</p> <p>N/A</p>
Ethics and dissemination		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Page 3</p> <p>This study was approved by Ethics Committee of China-Japan Friendship Hospital for Clinical Research (No. 2018-55-K39) .</p>
Protocol amendments	25	<p>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</p> <p>Page 5</p> <p>If there is any amendment to the protocol, approval must be sought again from the Ethics Committee.</p>
Consent or assent	26a	<p>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</p> <p>Page 6</p> <p>Patients will be recruited consecutively from the outpatient clinic of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p>
	26b	<p>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</p> <p>N/A</p>
Confidentiality	27	<p>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</p> <p>Page 11</p>

		All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality.
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site Page 14 The authors declare that they have no competing interests.
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators Page 11 Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care and for compensation to those who suffer harm from trial participation N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions Page 3 The results of this study will be disseminated via peer-reviewed publications and presentations at conferences.
	31b	Authorship eligibility guidelines and any intended use of professional writers N/A Topics suggested for publication will be circulated to the principal investigators.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		No intended use of professional writers. N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code No later than 3 years after the collection of the 3m postrandomization interviews, we will deliver a deidentified data set to an appropriate data archive for sharing purposes. N/A
Appendices		
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates A Chinese version of informed consent (V1.1, 20180208) has been reviewed and approved by the Ethics Committee of China-Japan Friendship Hospital for Clinical Research. N/A
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable N/A

BMJ Open

Effects of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure (HERE-CHF) : Study Protocol for a Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023923.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Dec-2018
Complete List of Authors:	Li, Jiahui; China-Japan Friendship Hospital, Cardiology Yang, Peng; China-Japan Friendship Hospital, Integrative Cardiology Fu, Dongliang; China-Japan Friendship Hospital, Integrative Cardiology Ye, Xiaojun; China-Japan Friendship Hospital, Cardiology Zhang, Lifang; China-Japan Friendship Hospital, Cardiology Chen, Gang; China-Japan Friendship Hospital, Rehabilitation Yang, Yiyun; China-Japan Friendship Hospital, Cardiology Luo, He; China-Japan Friendship Hospital, Cardiology Chen, Li; China-Japan Friendship Hospital, Phase I Clinical Ward of Clinical Trial Shao, Mingjing ; China-Japan Friendship Hospital, Integrative Cardiology Li, Chunyan; China-Japan Friendship Hospital, Integrative Cardiology Liu, Yi; China-Japan Friendship Hospital, Integrative Cardiology Zhou, Ying; China-Japan Friendship Hospital, Cardiology Jiang, Hong; China-Japan Friendship Hospital, Integrative Cardiology Li, Xianlun; China-Japan Friendship Hospital, Cardiology, Integrative Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Heart failure < CARDIOLOGY, REHABILITATION MEDICINE, Telemedicine < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™
Manuscripts

1
2
3
4 **Effects of Home-based Cardiac Exercise Rehabilitation with Remote**
5
6 **Electrocardiogram Monitoring in Patients with Chronic Heart Failure**
7
8 **(HERE-CHF) : Study Protocol for a Randomized Controlled Trial**
9
10

11 Jiahui Li^{1*}, Peng Yang^{2*}, Dongliang Fu², Xiaojun Ye¹, Lifang Zhang¹, Gang Chen³,
12
13 Yiyun Yang¹, He Luo¹, Li Chen⁴, Mingjing Shao², Chunyan Li², Yi Liu², Ying
14
15 Zhou¹, Hong Jiang^{2*}, Xianlun Li^{1,2*}
16
17

18
19 ¹Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China;
20

21
22 ²Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing
23
24 100029, China; ³Department of Rehabilitation, China-Japan Friendship Hospital,
25
26 Beijing 100029, China; ⁴Phase I Clinical Ward of Clinical Trial Research Center,
27
28 China-Japan Friendship Hospital, Beijing 100029, China.
29
30

31
32 * Jiahui Li and Peng Yang are joint first authors.
33

34
35 *Correspondence: Xianlun Li and Hong Jiang are both corresponding authors.
36

37
38 Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com.
39

40
41 Hong Jiang: Tel: + 86 15811227722, E-mail: drjh68@163.com.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

Patients with chronic heart failure (CHF) can benefit from exercise rehabilitation (ER) with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Despite its reported benefits, only a small number of patients with CHF attend ER due to poor adherence and improper exercise may even lead to adverse events. Remote electrocardiogram monitoring system (REMS) has the potential to overcome these obstacles. We hypothesize that home-based cardiac ER using REMS in CHF patients is effective compared with conventional ER without monitoring.

Methods and Analysis

This study is a prospective, randomized, parallel controlled clinical trial designed to evaluate the effectiveness of home-based phase-II ER with REMS in the treatment of CHF with a target enrollment of 120 patients 【Left Ventricular Ejection Fraction <50%, New York Heart Association (NYHA) classes I to III】. Patients are randomized to either REMS rehabilitation group or conventional rehabilitation group in a 1:1 ratio. All patients start an exercise training in a supervised setting and then transition to a home-based regimen. The supervised training phase consists of 12 supervised training sessions, 3 sessions per week for 4 weeks. During the home exercise phase, patients exercise 5 times per week for 8 weeks. In the REMS group, patients wear monitors during exercise to ensure that exercise intensity is within the set ranges. REMS will also detect risky arrhythmia and alert the patients and their doctors on time. The training intensity is not monitored in the conventional rehabilitation group. The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO_2 peak) (baseline vs 3 m). Secondary outcomes include 6-min Walk Test (6MWT), NYHA classes, echocardiographic parameters, cardiac biomarkers, major adverse cardiovascular events (MACE), quality of life, psychological well-being and patients' adherence to the rehabilitation program.

Ethics and Dissemination

1
2
3
4 This study was approved by Ethics Committee of China-Japan Friendship Hospital for
5
6 Clinical Research (No. 2018-55-K39) . The results of this study will be disseminated
7
8 via peer-reviewed publications and presentations at conferences.
9

10 **Clinical trial registration number**

11
12 ChiCTR-RNR-17012446
13

14 **Strengths and limitations of this study**

- 15
16
17 1. The wearable monitor used in this study is portable, which can evaluate patients'
18 exercise intensity based on their heart rate and then remind them to exercise
19 appropriately.
20
21 2. The REMS used here can detect arrhythmia and provide an early warning to both
22 the exercising patients and their doctors to further reduce risks.
23
24 3. Our cardiac ER program is home-based and convenient for CHF patients compared
25 with facility-based ER, which may provide new insights into cardiac
26 telerehabilitation in patients with CHF.
27
28 4. The main limitation of this single-center study is the small sample size.
29
30 5. A long-term follow-up may also be needed and extending the exercise out to 6
31 months may give us better data on adherence.
32
33
34
35
36
37
38
39
40

41 **Keywords:** Cardiac exercise rehabilitation, Telerehabilitation, Chronic heart failure,
42 Remote Electrocardiogram Monitoring System
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Heart failure (HF) is a complex clinical syndrome caused by abnormal cardiac structure or function which results in impaired ventricular filling or ejection ability. It is a terminal stage of various cardiovascular diseases, which has become the global public health problem of great concern. The prevalence of HF in the entire population is approximately 1.5%-2% and 6%-10% over 65 years of age [1]. Nowadays, due to modern therapies, more and more people are spared from acute cardiovascular attacks and the concomitant burden of chronic HF (CHF) is also increasing globally. According to the 2017 China Cardiovascular report[2], there are currently 8-10 million HF patients in China, and the prevalence rate increases significantly with age. The 5-year survival rate of HF patients with clinical symptoms is 50% , similar to that of malignant tumors[1]. For HF patients, repeated visits and hospitalizations place heavy financial burdens on individuals, families and society.

Many HF patients on optimal cardiovascular medical therapy still suffer from dyspnea and exercise intolerance. In addition to medical treatment and device therapy, successful cardiac rehabilitation (CR) is a valuable intervention for improving aerobic fitness and overall health status in patients with HF. HF patients can benefit from proper exercise with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations[3-6]. Exercise training is a core component of primary and secondary prevention for HF, which has been recommended by relevant international professional associations[3-6].

Despite its reported benefits, a limited number of HF patients regularly participate in exercise rehabilitation (ER) , primarily because of poor patients' adherence. In addition, inappropriate exercise that is not monitored may even cause adverse cardiovascular events such as myocardial infarction, arrhythmias and sudden death. HF-A Controlled Trial Investigating Outcomes of exercise training (HF-ACTION)[7] is the largest multicenter clinical study of ER in HF, which randomly assigned 2331 patients to either exercise training or usual care. Only 42% of the subjects in their cohort completed all three scheduled follow-up exercise tests and 33% and 25% completed

1
2
3
4 two and one of their scheduled follow-up exercise tests, respectively. Given the
5
6 observed effect between higher adherence and improved outcomes, it is more important
7
8 to provide cardiac ER programs which can achieve increased adherence to the exercise
9
10 intervention [8].

11
12 Cardiac telerehabilitation using monitoring devices and remote communication with
13
14 patients is now increasingly used for long-term management of cardiovascular diseases
15
16 outside the hospital environment. Providing objective feedback data and allowing
17
18 patients to track their own progress can improve patients' self-management skills and
19
20 thereby improve their adherence. It is convenient and can reduce anxiety, improve the
21
22 quality of life and prognosis of patients with low medical costs compared with
23
24 conventional ER without monitoring [9-13].

25
26 This study is a prospective, randomized, parallel controlled clinical trial to evaluate the
27
28 effectiveness and safety of home-based phase-II ER under the guidance of remote
29
30 electrocardiogram (ECG) monitoring system (REMS) in the management of
31
32 CHF compared with conventional ER without monitoring. This paper describes the
33
34 design and rationale of the **HERE-CHF** trial.

35 36 **Methods/design**

37 38 *Design*

39
40 A flow chart of the study design is shown in Figure 1. The protocol is constructed and
41
42 presented in accordance with the recommendations for Interventional Trials (SPIRIT)
43
44 [14]. The study protocol (V1.1, 20180208) and informed consent documents (V1.1,
45
46 20180208) have been reviewed and approved by the Ethics Committee of China-Japan
47
48 Friendship Hospital for Clinical Research. If there is any amendment to the protocol,
49
50 approval must be sought again from the Ethics Committee. The study strategy has been
51
52 registered on the website of Chinese Clinical Trial Registry (ChiCTR-RNR-17012446,
53
54 registered on 22 August 2017), and the trial will be conducted in accordance with the
55
56 principles of the Declaration of Helsinki and Good Clinical Practice guidelines.

57 58 *Eligibility and recruitment*

59
60 Patient selection criteria are listed in Table 1. Patients must have a systolic cardiac

1
2
3
4 dysfunction documented from a baseline echocardiogram 【 LV ejection fraction
5
6 (LVEF) <50%】 and are in stable conditions 【New York Heart Association (NYHA)
7
8 classes I to III】 within 6 weeks prior to randomization. According to the American
9
10 College of Cardiology(ACC)/American Heart Association (AHA) HF guidelines,
11
12 stable optimal drug therapies including β blockers, diuretics, angiotensin-converting
13
14 enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) and aldosterone
15
16 receptor antagonists for 6 weeks before enrollment is strongly advocated. If patients are
17
18 not treated with optimal medical therapy, then trial personnel must document the
19
20 underlying reason (eg, drug intolerance).
21
22

23 Patients enrollment began in April 2018. Patients were recruited consecutively from the
24
25 outpatient service of Cardiology Department and Integrative Cardiology Department in
26
27 China-Japan Friendship Hospital by attending physicians responsible for recruitment,
28
29 who had obtained written consent from patients who were willing to participate in the
30
31 trial. Screening will continue until the target population is achieved. A recruitment
32
33 advertisement has also been utilized in our hospital. No financial incentives were
34
35 provided to the attending physicians or patients for enrollment.
36

37 ***Sample size***

38 The target number of participants in the trial is 120 subjects. A total of 500 HF patients
39
40 (NYHA grade I-III) are treated in our hospital each year and can be used as a screening
41
42 sample. Based on the lower screening rate (50%) and the designed entry criteria, the
43
44 sample size that can be completed is estimated to be 100 patients. With reference to
45
46 previous foreign literature, the compliance of ER within 3 months is 70-80%. The study
47
48 will enroll at least 120 subjects, 60 subjects in each group.
49

50 ***Exercise testing***

51 The prerandomization cardiopulmonary exercise testing (CPET) is used to determine
52
53 whether patients can exercise safely in according with the guidelines of the American
54
55 Association of Cardiovascular and Pulmonary Rehabilitation, including checking for
56
57 abnormal blood pressure responses, early ischemic changes, and significant
58
59 arrhythmias. Exercise testing is repeated 3 month after randomization for all patients.
60

1
2
3
4 The primary method used for exercise testing is cycling, consistent with AHA
5 guidelines and with other trials that have assessed exercise capacity in patients with HF.
6

7 ***Randomization and binding***

8
9 The clinical research data management platform of China-Japan Friendship Hospital
10 was commissioned to generate a random sequence of 120 numbers using SAS 9.4
11 software. The random sequence is placed into a sealed envelope by a staff member who
12 is not involved in the study to avoid selection bias. After providing informed consent
13 and undergoing baseline testing (echocardiogram and CPET), patients are randomly
14 assigned to the REMS rehabilitation group or the conventional rehabilitation group in
15 a 1:1 ratio based on the patient's admission time. Allocation concealment is ensured
16 and the randomization code will not be released until the patient has been recruited into
17 the trial, which takes place after all baseline measurements have been completed.
18
19 Researchers involved in participants' assessments are blinded to treatment allocation.
20
21
22
23
24
25
26
27
28

29 ***Trial structure***

30 The trial structure of the study is described in the Table 2.
31

32 ***REMS***

33
34 Inticare-MC-06 wearable ECG monitor (Elephant Medical Electronic Technology Co. ,
35 Ltd, Jining, China), approved by Food and Drug Administration in Shandong province
36 of China (Certificate No. Shandong Medical Device Registration Approval
37 20172210878) is a medical-grade portable cardiac monitor and looks like a smaller
38 "Band-Aid" that can collect 48 hours of single-lead ECG data. It can provide cardiac
39 care service through a "Hardware + Software+ Cloud + Doctor" program, and support
40 arrhythmia automatic trigger and One-Tap SOS. Inticare-MC-06 heart health monitor
41 solution consists of five parts: a wearable ECG monitor, mobile terminals (such as
42 smart phones), Cardiac Healthcare Cloud Service platform of Elephant Medical
43
44 (Tianjin AI-Life Medical Technology Co. , Ltd, China) , cardiologists and
45 monitoring reports, supported by Tianjin Institute of Internet of Things Technology.
46
47 The wearable ECG monitor is pasted on the chest through one-piece electrodes and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 transfers the ECG data to the smart phone application of cloud service platform
5 (Elephant Heart Health) via bluetooth smart technology. If an electrocardiogram such
6 as arrhythmia occurs during exercise, the system will alert the patient to stop or suspend
7 exercise, or adjust the intensity of exercise, and upload it in real time. The data will be
8 transformed to the data center, and the specialist will analyze that report. The unique
9 algorithm analyzes the data in real time and detects suspicious arrhythmias, then sends
10 out alerts and transfers data to cloud platform for doctors to check and confirm the
11 disease. In addition, when patients have chest discomfort, palpitation and dizziness,
12 they can mark the ECG data through One-Tap Marking button and send the data for
13 doctors to check and give corresponding diagnosis. At the end of the monitoring, a
14 report will be provided.

25 ***Interventions***

26
27 All the patients initiate an exercise training program in accordance with the principles
28 of exercise prescription recommended by the American College of Sports Medicine
29 (ACSM) and the AHA. The sequence of the exercise phase can be warm-up, main
30 exercise, and cool-down. For the warm-up and cool-down, walking or light stretching
31 is recommended. The main exercise is walking. Exercise training initially begins in a
32 supervised setting and then transitions to a home-based regimen (Table 3 and Table
33 4) . The supervised training phase consists of 12 supervised training sessions, with a
34 goal of 3 sessions per week. It takes up to 1 month for patients to complete the 12
35 sessions before transition to the home exercise phase. Patients are required to exercise
36 5 times per week during the home exercise phase for a total of 8 weeks. Patients begin
37 exercising at a low intensity and then increase to a moderate intensity when they are
38 able to do so. The trial protocol allows patients to walk independently.

39
40 In the REMS group, patients wear Inticare-MC-06 ECG monitors while exercising at
41 home to ensure that exercise intensity is within their set ranges and are instructed on
42 how to monitor their own exercise training at the beginning of the trial. During the
43 exercise, the monitor can evaluate whether patients have reached the intensity and time
44 of the preset exercise prescription based on the heart rate. If the speed is not enough or
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 the intensity exceeds the preset value, the system can remind the patient promptly to
5 adjust the intensity, including speed and time course, to ensure that the patient to
6 exercise based on the prescription. If arrhythmia occur during exercise, the system will
7 alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and
8 upload it in real time. Specialists will give an analysis report. The system will give an
9 early warning to both patients and their doctors if the arrhythmia is risky. Doctors can
10 check data from patients outside hospital to understand their conditions and provide
11 timely advice.
12

13
14
15
16
17
18
19 The heart rate reserve (HRR) method is used to guide exercise intensity. Peak heart rate
20 is derived from a patient's most recent exercise test, and the resting heart rate is taken
21 after a quiet seated rest for 5 minutes. For the first 6 supervised training sessions, the
22 training heart rate range is calculated as 60% of the HRR (resting heart rate + 0.6 [peak
23 heart rate-resting heart rate]). Then training intensity is increased to 70% of the HRR
24 for the rest of the supervised exercise training sessions. For the home-based exercise
25 training phase, patients are asked to perform 40 minutes of aerobic exercise. In the
26 REMS training arm, the training intensity should be maintained at 60% to 70% of the
27 HRR. The training intensity is not monitored during the entire phase of the
28 conventional rehabilitation arm..
29
30
31
32
33
34
35
36
37

38 ***Concomitant treatment***

39
40 Participants in both groups continue to receive standard treatment for HF. The
41 medication should remain unchanged during the trial and the dosage should be adjusted
42 in the event of adverse events. All procedures are determined by physicians following
43 the clinical guidelines.
44
45
46
47

48 ***Adherence***

49
50 During the training phase, participants are required to exercise in strict accordance with
51 the prescription and use the designed cards to record each exercise process.
52 Investigators make telephone reminders before each visit and then provide face-to-face
53 reminders on each study visit to emphasize the importance of adherence. Compliance
54 of ER in subjects are expressed in rate.
55
56
57
58
59

60 ***Outcome assessments***

1
2
3
4 The primary outcome is an improvement in exercise capacity measured by peak oxygen
5 uptake (VO_2 peak) (baseline vs 3 m). The secondary outcomes are: (1) difference in the
6 meters walked in the 6-min Walk Test (6MWT); (2) improvement in heart function
7 assessed by NYHA classifications; (3) improvement in echocardiographic parameters
8 of systolic and diastolic function; (4) changes in biomarkers, including brain natriuretic
9 peptide (BNP) / N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and
10 Troponin-T/I; (5) changes in major adverse cardiovascular events (MACE) including
11 worsening HF event, HF hospitalization, myocardial infarction, stroke,
12 revascularization and cardiovascular mortality; (6) qualitative evaluation of patients'
13 adherence to the rehabilitation program. The investigators also use several validated
14 psychometric instruments to measure health-related quality of life and depression.
15
16 These measurements include HF Symptom Scale , Minnesota Living with Heart
17 Failure Questionnaire (MLHFQ), 36-Item Short Form Health Survey (SF-36), Beck
18 Depression Inventory-II (BDI-II) and General Self-Efficacy Scale (GSE). Researchers
19 involved in participants' assessments will be blinded to treatment allocation.

34 ***Withdrawal***

35
36 According to Ethics Committee of Clinical Research legislations of China-Japan
37 Friendship Hospital, we inform the patients about their rights as subjects in a scientific
38 trial and about their rights to terminate. We do this to allow patients to fully consider
39 participation thoroughly to reduce their likelihood of dropping out of the study. Patients
40 may withdraw from the trial at their own request or at the request of their legal
41 representative at any time.

47 ***Data collection, management, and analysis***

48
49 All patients' data are recorded by trained clinical researchers using a standardized case
50 report form (CRF). Raw data should be recorded in timely and accurate manner. Copies
51 of laboratory reports should also be kept. All CRFs are stored in locked file cabinets in
52 areas with limited access. All laboratory specimens are identified by a coded number
53 to maintain participant confidentiality. Data administrators from Cardiar Technology
54 in Beijing, China are responsible for the data entry and management. The database was
55
56
57
58
59
60

1
2
3
4 built using PHP language under Linux system. Two data managers independently
5 perform dual input and proofreading to ensure data accuracy. The clinical research data
6 management platform of China-Japan Friendship Hospital is responsible for data
7 monitoring, which is independent of the study organizers. All individuals involved in
8 data management and analysis are blinded to treatment allocation. Principal
9 investigators have direct access to data sets. Data dispersed to project team members
10 are blinded of any identifying participant information.

11 12 13 ***Adverse events monitoring***

14 All adverse events that occurred during the 3-month study period will be reported in
15 the final paper. A serious adverse event is defined as any untoward medical occurrence
16 resulting in hospitalization or which results in a life-threatening problem, death, or
17 disability. Adverse events are defined as any untoward occurrences in study participants,
18 potentially related to implementation of the study protocol. All serious and unexpected
19 adverse events will be reported to the Ethics Committee as required.

20 21 22 ***Statistical analysis***

23 Continuous variables will be presented as the mean \pm standard deviation (SD), median
24 or interquartile range (IQR). Baseline characteristics of the cohort will be summarized
25 using descriptive statistics. Whether there are imbalances will be analyzed between
26 groups. When normally distributed, independent samples will be compared for
27 numerical variables between the two groups using Student's t-test. The categorical
28 variables described as frequencies and percentages will be compared using Chi-square
29 test. Mann-Whitney U test will be used if data are not normally distributed.

30 Analysis of outcomes will be conducted based on the intention-to-treat (ITT) principle.

31 We will use three sets of analysis: full analysis set (FAS) , per protocol set (PPS)
32 and safety set. The FAS includes all randomized patients, and the PPS consists of all
33 patients who complete the treatment protocol. The safety set consists of patients who
34 receive at least one treatment with safety records after randomization. Dropouts will be
35 included in the analysis by modern imputation methods for missing data.

36 All statistical tests will be 2-tailed. $P < 0.05$ is considered statistically significant. All

1
2
3
4 statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd using
5 SAS 9.4 software.
6

7 ***Patient and Public Involvement (PPI)***

8
9 During the study design period, CHF patients and their relatives were invited to
10 participate in surveys and discussions, which allowed us to know their strong desire in
11 ER, especially home-based telerehabilitation. We also selected several patients to use
12 the monitor, which helped us to identify problems in application. In addition, we invited
13 medical specialists including cardiologists, rehabilitation therapists and statistical
14 analysts to discuss the study design and revise the intervention method and outcome
15 measures. The results of our study will be disseminated to PPI representatives and study
16 participants who wish to be notified.
17
18
19
20
21
22
23
24

25 **Discussion**

26
27 **HERE-CHF** evaluates the effect of cardiac telerehabilitation intervention that
28 combines modern technology (sensor technology, internet and remote consultation)
29 with evidence-based ER guidance strategies, including prevention of adverse events
30 during exercising. The objective of this study is to investigate whether home-based
31 cardiac ER using REMS is superior to conventional ER without monitoring in CHF
32 patients. We hypothesize that this intervention will improve physical activity levels and
33 quality of life.
34
35
36
37
38
39
40
41

42 Home-based CR is a method to increase the ER participation rate in HF patients.
43 Whether exercise prescription can be performed effectively and the safety in exercise
44 are two main issues in home-based ER. While exercise intensity is the key of exercise
45 prescription because the exercise must be appropriate. Heart rate is the most important
46 factor to monitor the patient's exercise intensity. Our wearable ECG monitor can
47 evaluate whether patients reach the intensity based on the heart rate and promptly alert
48 the patients to ensure that exercise intensity is within the preset range. REMS will also
49 detect risky arrhythmia and provide an early warning to both the patients and their
50 doctors, which can encourage patients to overcome fear and adhere to exercise. The use
51 of our REMS offers a prospect for the delivery and expansion of home-based cardiac
52
53
54
55
56
57
58
59
60

ER programs in HF patients beyond the supervised setting and will help to increase adherence, reduce risk factors and improve benefit-cost ratio , which may further enhance the effectiveness of ER.

CPET can be used to evaluate patient exercise capacity and exertional symptoms and can provide numerous physiologic parameters. Multiple CPET-derived variables have been assessed for their association with mortality in systolic HF patients and peak VO_2 is shown to be the strongest predictor of mortality [15]. Therefore , we select it as the primary outcome in **HERE-CHF**. The 6MWT is chosen as a secondary outcome due to its useful prognostic information similar to peak VO_2 [16]. 6MWT is less expensive and much more convenient in comparison to the nontrivial costs of CPET with its distinctive value as a measure of routine activity. Quality of life and psychological state are important in the evaluation of home-based ER, which are also included in our study.

Conclusion

The **HERE-CHF** study will provide new insights into the effect of home-based cardiac ER guided by REMS. Our REMS will help to increase adherence and reduce risk factors for HF patients, which may further enhance the effectiveness of ER.

Acknowledgements

The authors thank all the patients advisers and medical students for their assistance in the study.

Contributors

Xianlun Li, Hong Jiang, Jiahui Li and Peng Yang conceived the original concept of the study, registered the trial and wrote the draft of the protocol manuscript. Dongliang Fu, Xiaojun Ye, Lifang Zhang, Gang Chen, Yiyun Yang, He Luo, Li Chen , Mingjing Shao , Chunyan Li, Yi Liu and Ying Zhou contributed to the design of the study. All the authors read and discussed the manuscript, and approved the final version.

Funding

This work is financially supported by China Capital Health Development Research

1
2
3
4 Special Fund (2018-2-4064) . Inticare-MC-06 ECG monitors are provided by Tianjin
5
6 AI-Life Medical Technology Co. , Ltd, China. The funding source does not influence
7
8 or comment on planned methods, protocol, data analysis, or the draft report.
9

10 **Competing interests**

11
12
13 The authors declare that they have no competing interests.
14
15

16 **References**

- 17
18
19
20 1. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of
21 Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic
22 heart failure. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2007 Dec; 35(12):1076-95.
23
- 24
25
26 2. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, Wu ZS, Li HJ, Gu
27 DF, Yang YJ, Zheng Z, Jiang LX, Hu SS Representative group of Chinese
28 cardiovascular diseases report. Report on cardiovascular diseases in China (2017) .
29 Chinese Circulation Journal. 2018; 33(1):1-7.
30
31
- 32
33
34 3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC,
35 Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA,
36 McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW,
37 Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American
38 Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the
39 management of heart failure: a report of the American College of Cardiology
40 Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll*
41 *Cardiol*. 2013 Oct 15;62(16):e147-239.
42
43
- 44
45
46 4. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of
47 Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of
48 heart failure 2014. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2014 Feb;42(2):98-122.
49
50
- 51
52
53 5. Chinese Rehabilitation Medical Association Professional Committee of Cardiovascular
54 Diseases; Committee of Cardio-Cerebral-Vascular Diseases of GSC. Chinese expert
55
56
57
58
59
60

- 1
2
3
4 consensus on cardiac rehabilitation for patients with chronic stable heart failure.
5
6 *Zhonghua Xin Xue Guan Bing Za Zhi*. 2014 Sep;42(9):714-20.
- 7
8 6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-
9
10 Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P,
11
12 Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van
13
14 der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines
15
16 for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the
17
18 diagnosis and treatment of acute and chronic heart failure of the European Society of
19
20 Cardiology (ESC). Developed with the special contribution of the Heart Failure
21
22 Association (HFA) of the ESC. *Eur J Heart Fail*. 2016 Aug;18(8):891-975.
- 23
24 7. Keteyian SJ, Isaac D, Thadani U, Roy BA, Bensimhon DR, McKelvie R, Russell SD,
25
26 Hellkamp AS, Kraus WE; HF-ACTION Investigators. Safety of symptom-limited
27
28 cardiopulmonary exercise testing in patients with chronic heart failure due to severe left
29
30 ventricular systolic dysfunction. *Am Heart J*. 2009 Oct;158(4 Suppl):S72-7.
- 31
32 8. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training
33
34 Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac
35
36 Rehabilitation: A Systematic Review and Meta-regression. *Sports Med Open*. 2017 Dec;
37
38 3(1):19.
- 39
40 9. Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative models
41
42 of cardiac rehabilitation: a systematic review[J]. *Eur J Prev Cardiol*. 2015 Jan; 22(1):35-
43
44 74.
- 45
46 10. Lee Y, Lee J, Seo H, Kim K, Min D, Lee J, Choi J. Effects of Home-based Exercise
47
48 Training with Wireless Monitoring on the Left Ventricular Function of Acute Coronary
49
50 Syndrome Patients. *J Phys Ther Sci*. 2013 May;25(5):631-3.
- 51
52 11. Chung H, Ko H, Thap T, Jeong C, Noh SE, Yoon KH, Lee J. Smartphone-Based Cardiac
53
54 Rehabilitation Program: Feasibility Study. *PLoS One*. 2016 Aug 23;11(8):e0161268.
- 55
56 12. Hwang R, Bruning J, Morris NR, Mandrusiak A, Russell T. Home-based
57
58 telerehabilitation is not inferior to a centre-based program in patients with chronic heart
59
60 failure: a randomised trial. *J Physiother*. 2017 Apr;63(2):101-107.

- 1
2
3
4 13. Di Lenarda A, Casolo G, Gulizia MM, Aspromonte N, Scalvini S, Mortara A, Alunni G,
5 Ricci RP, Mantovan R, Russo G, Gensini GF, Romeo F. The future of telemedicine for
6 the management of heart failure patients: a Consensus Document of the Italian
7 Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology
8 (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). *Eur Heart J*
9 *Suppl.* 2017 May;19(Suppl D):D113-D129.
- 10
11
12
13
14
15 14. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance
16 for content of clinical trial protocols. *Lancet.* 2013; 381(9861):91–2.
- 17
18
19 15. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, Leifer ES, Fleg
20 JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, O'Connor CM, Ehrman JK,
21 Walsh MN, Ewald G, Bensimhon D, Russell SD; HF-ACTION Investigators. Variables
22 Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in
23 Chronic Systolic Heart Failure. *J Am Coll Cardiol.* 2016 Feb 23;67(7):780-9.
- 24
25
26
27
28
29 16. Daniel E. Forman, Jerome L. Fleg, Dalane Kitzman, Clinton A. Brawner, Ann Swank,
30 Robert McKelvie, Robert Clare, Stephen J. Ellis, Mark E. Dunlap, Vera Bittner. 6 Minute
31 Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary Exercise Testing
32 in Ambulatory Outpatients with Systolic Heart Failure. *J Am Coll Cardiol.* 2012 Dec 25;
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 60(25): 2653–2661.

Table 1. HERE-CHF trial inclusion and exclusion criteria

Inclusion criteria

1. Aged 18-75 years old;
2. NYHA I-III; LVEF<50% in 6 weeks before randomization;
3. in stable condition after heart failure standard drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device), no fluid retention, constant weight;
4. able to perform exercise rehabilitation;
5. clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

1. exercise rehabilitation can not be carried out due to physical disability and contraindication;
 2. with a contraindication to cardiopulmonary exercise test;
 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid artery or other major vascular surgery; percutaneous coronary intervention (PCI) or carotid artery angioplasty; sustained ventricular tachycardia or fibrillation;
 4. coronary revascularization or heart transplantation is planned;
 5. persistent atrial arrhythmias ; ventricular arrhythmias were not effectively controlled (using an antiarrhythmic drug or an implantable defibrillator);
 6. uncorrected primary obstructive or severe regurgitant heart valve disease, restrictive or hypertrophic cardiomyopathy;
 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker implantation; need implantable device therapy for heart failure;
 8. obstructive or bronchospasm lung disease(such as asthma, bronchitis, etc) needing oral or inhaled bronchodilator or glucocorticoids therapy;
 9. pregnant or lactating women and those planning to conceive during the trial;
 10. cancer or other systemic diseases with an expected survival of less than 12 months;
 11. other clinical trial drugs were taken or in other medical device trial within 30 days before admission;
 12. unable to participate in this study after the clinical evaluation by investigators.
-

Table 2 Trial structure of the study

Time Assessment	Screening (-14--1d)	Exercise Rehabilitation in Clinic			Exercise Rehabilitation at Home	
		T0 Visit 1 Baseline	T1 Visit 2 2 nd weekend	T2 Visit 3 4 th weekend	T3 Visit 4 8 th weekend	T4 Visit 5 12 th weekend
medical history	√					
Inclusion/Exclusion Form	√					
Consent Form	√					
Comorbidity	√	√	√	√	√	√
Concomitant medication	√	√	√	√	√	√
Physical examination	√	√	√	√	√	√
Troponin T/I		√				√
BNP/NT-proBNP		√				√
Electrocardiogram	√	√		√	√	√
Holter	√					√
NYHA classification	√	√		√	√	√
Echocardiography	√	√				√
CPET	√					√
6MWT		√				√
Heart failure symptom scale		√				√

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

MLHFQ		√				√
SF-36		√				√
BDI-II		√				√
GSE		√				√
Compliance				√	√	√
Adverse event			√	√	√	√
Monitor and APP training		√				

The time window for each visit is $\pm 3d$. MLHFQ: Minnesota Living with Heart Failure Questionnaire. SF-36: 36-Item Short Form Health Survey.
 BDI-II: Beck Depression Inventory. GSE: General Self-Efficacy Scale.

Table 3. Exercise training program in remote ECG monitoring system rehabilitation group

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	2	3	15-30	60	walk
supervised by Rehabilitation specialist	Clinic	2	3	15-30	70	walk
Supervised by remote ECG monitoring	home	8	5	40	60-70	walk

Table 4. Exercise training program in conventional rehabilitation group without monitoring

Training phase	Location	week	Weekly sessions	Aerobic duration (min)	Intensity (percentage of HRR)	Mode of exercise
Initial, supervised by Rehabilitation specialist	Clinic	4	3	15-30	without monitoring	walk
Symptom-Limited, self-adaption	home	8	5	40	without monitoring	walk

1
2
3
4
5 **Legends**
6

7 **Figure 1 Study flow chart.** CPET: cardiopulmonary exercise testing. 6MWT: 6-min
8

9 Walk Test. REMS : remote electrocardiogram monitoring system.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Study flow chart. CPET: cardiopulmonary exercise testing. 6MWT: 6-min Walk Test. REMS : remote electrocardiogram monitoring system.

90x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

SPIRIT 2013 checklist

Section/item	ItemNo	Information
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym page 1 Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure (HERE-CHF) : Study Protocol for a Randomized Controlled Trial page 1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry page 3 www.chictr.org.cn ChiCTR-RNR-17012446
	2b	All items from the World Health Organization Trial Registration Data Set N/A Registration number : ChiCTR-RNR-17012446 Date of Last Refreshed on : 2017/8/22 10:09:47 Registration Status : 1008001 Prospective registration Public title : An Exploratory Clinical Study on Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart

		Failure	
	Scientific title :	An Exploratory Clinical Study on Effect of Home-based Cardiac Exercise Rehabilitation with Remote Electrocardiogram Monitoring in Patients with Chronic Heart Failure	
	Applicant :	Li Jiahui	Study leader : Li Xianlun
	Applicant telephone :	+86 13436354344	Study leader's telephone : +86 13910812495
	Applicant E-mail :	veighlee@163.com	Study leader's E-mail : leexianlun@163.com
	Applicant address :	2 Yinghua Street East, Chaoyang District, Beijing, China , 100029	Study leader's address : 2 Yinghua Street East, Chaoyang District, Beijing, China ,100029
	Applicant's institution : China-Japan Friendship Hospital		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>Primary sponsor : China-Japan Friendship Hospital</p> <p>Primary sponsor's address : 2 Yinghua Street East, Chaoyang District, Beijing, China</p> <p>Source(s) of funding : Self-financing</p> <p>Target disease : heart failure</p> <p>Study type : Relative factors research</p> <p>Study phase : New Treatment Measure Clinical Study</p> <p>Objectives of Study :</p> <p>To evaluate the efficacy and safety of home-based cardiac exercise rehabilitation with remote electrocardiogram(ECG) monitoring in patients with chronic heart failure(NYHA classification I-III).To demonstrate that home-based exercise rehabilitation with remote ECG monitoring has the advantages of standardization and easy implementation compared with traditional exercise rehabilitation.</p> <p>Study design :</p> <p>Randomized parallel controlled trial</p> <p>Inclusion criteria</p> <p>(1) Aged 18-75 years old, male or female; (2) chronic heart failure (NYHA classification I-III); LVEF<50% in 6 weeks before randomization; (3) in stable condition after heart failure standard</p>
--	--

1
2
3
4
5 drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular
6 assist device),no fluid retention,constant weight; (4) able to perform exercise rehabilitation; (5)
7 clearly understand the content and purpose of the study and volunteer to participate in the study
8 and sign the informed consent form.
9

10
11
12 Exclusion criteria :

13
14 1. exercise rehabilitation can not be carried out due to physical disability and contraindication; 2.
15 with a contraindication to cardiopulmonary exercise test; 3. the following was happened in 3
16 months before admission: acute coronary syndrome, stroke, transient ischemic
17 attack;cardiac,carotid artery or other major vascular surgery;percutaneous coronary intervention
18 (PCI)or carotid artery angioplasty;sustained ventricular tachycardia or fibrillation; 4. coronary
19 revascularization or heart transplantation is planned; 5. ventricular arrhythmias were not
20 effectively controlled (using an antiarrhythmic drug or an implantable defibrillator); 6.
21 uncorrected primary obstructive or severe regurgitant heart valve disease,restrictive or
22 hypertrophic cardiomyopathy; 7. II or III degree heart block or sick sinus syndrome without
23 permanent pacemaker implantation; need implantable device therapy for heart failure; 8.
24 obstructive or bronchospasm lung disease(such as asthma, bronchitis,etc) needing oral or inhaled
25 bronchodilator or glucocorticoids therapy; 9. pregnant or lactating women and those planning to
26 conceive during the trial; 10. cancer or other systemic diseases with an expected survival of less
27 than 12 months; 11. other clinical trial drugs were taken or in other medical device trial within 30
28 days before admission; 12. unable to participate in this study after the clinical evaluation by
29
30
31
32
33
34
35
36
37
38
39
40

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>investigators.</p> <p>Study execute time : From2018/01/01 To 2020/12/31</p> <p>Interventions :</p> <p>Remote electrocardiogram monitoring group Sample size : 60</p> <p>Control group without monitoring Sample size : 60</p> <p>Countries of recruitment and research settings : China-Japan Friendship Hospital,China</p> <p>Level of the institution : Tertiary A hospital</p> <p>Outcomes : VO2Peak , 6 minute walk distance , left ventricular ejection fraction, blood test</p> <p>Randomization Procedure (please state who generates the random number sequence and by what method) :</p> <p>The clinical data management platform of China-Japan Friendship Hospital is commissioned to create SAS 9.4 software to generate random concealment table tables. Masked envelopes will be produced by random concealment and participants are admitted by 1:1 random principle.</p> <p>The time of sharing IPD : Within six months after the trial complete</p> <p>The way of sharing IPD" (include metadata and protocol, If use web-based public database, please</p>
--	---

		provide the url) : Publish original data by June 2021 in the form of meetings, speeches or articles.
Protocol version	3	Date and version identifier page 5 20180208 V1.1
Funding	4	Sources and types of financial, material, and other support page 13 This work is financially supported by China Capital Health Development Research Special Fund (2018-2-4064) . Inticare-MC-06 ECG monitors are provided by Tianjin AI-Life Medical Technology Co. , Ltd, China. The funding source does not influence or comment on planned methods, protocol, data analysis, or the draft report.
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors page1, 13 Jiahui Li1*, Peng Yang2*, Dongliang Fu2, Xiaojun Ye1, Lifang Zhang1, Gang Chen3, Yiyun Yang1, He Luo1, Li Chen4 , Mingjing Shao2 , Chunyan Li2, Yi Liu2 , Ying Zhou1, Hong Jiang2 ✧, Xianlun Li1,2✧ 1Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China; 2Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing 100029, China; 3Department of Rehabilitation, China-Japan Friendship Hospital, Beijing 100029, China; 4Phase I Clinical Ward of Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing 100029, China.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>✘ Correspondence: Xianlun Li and Hong Jiang are both corresponding authors.</p> <p>Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com. Hong Jiang: Tel: + 86 15811227722, E-mail: drjh68@163.com.</p> <p>Xianlun Li, Hong Jiang, Jiahui Li and Peng Yang conceived the original concept of the study and wrote the draft of the protocol manuscript. Other authors contributed to the design of the study. All authors approved the final manuscript.</p>
5b	<p>Name and contact information for the trial sponsor page 1</p> <p>Trial sponsor: Beijing Municipal Commission of Health and Family Planning Telephone: 86-10-83970661 Principal investigator: Xianlun Li: Tel: + 86 13910812495, E-mail: leexianlun@163.com.</p>
5c	<p>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities page 13</p> <p>The funding source does not influence or comment on planned methods, protocol, data analysis, or the draft report.</p>
5d	<p>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) page 6,7,10-11,</p>

		<p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to generate a random sequence of 120 numbers using SAS 9.4 software. The random sequence will be put into sealed envelopes by staff not involved with the study to avoid selecting bias.</p> <p>Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organisers.</p> <p>All statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd using SAS 9.4 software.</p>
Introduction		
Background and rationale	6a	<p>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention Page 4,5</p> <p>Heart failure (HF) is a complex clinical syndrome caused by abnormal cardiac structure or function which results in impaired ventricular filling or ejection ability. It is a terminal stage of</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<p>various cardiovascular diseases, which has become the global public health problem of great concern. The prevalence of HF in the whole population is approximately 1.5%-2% and 6%-10% over 65 years of age [1]. More and more individuals are surviving an acute cardiovascular attack due to modern therapies now and the concomitant burden of chronic HF (CHF) is also increasing worldwide. At present, there are 8-10 million patients with HF in China, and the prevalence rate increases significantly with age according to China Cardiovascular report 2017[2]. The 5-year survival rate of HF patients with clinical symptoms is 50% ,similar to that of malignant tumors[1].</p> <p>Repeated visits and hospitalizations of HF patients bring heavy economic burdens to individuals, families and society.</p> <p>Many HF patients on optimal cardiovascular medical therapy still suffer from dyspnea and exercise intolerance. In addition to medical treatment and device therapy, successful cardiac rehabilitation (CR) is a valuable intervention for improving aerobic fitness and overall health status in patients with HF. There is a growing consensus that exercise has a beneficial effect on patients with cardiovascular disease, even for those with severely impaired cardiac function. HF patients can benefit from proper exercise with significant improvements in exercise capacity, quality of life, and reduction in hospitalizations. Exercise training is a core component of primary and secondary prevention, which has been recommended by relevant international professional associations[3-6].</p> <p>Despite its reported benefits, a limited number of HF patients attend exercise rehabilitation (ER)</p>
--	---

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>on a regular basis mainly because of poor patients' adherence. Furthermore, improper exercise without monitoring may even cause adverse cardiovascular events such as myocardial infarction, arrhythmias and sudden death. HF-A Controlled Trial Investigating Outcomes of exercise training (HF-ACTION)[7] is the largest multicenter clinical study of ER in HF, which randomly assigned 2331 patients to either exercise training or usual care. Only Forty-two percent of subjects in their cohort completed all three of their scheduled follow-up exercise tests and 33% and 25% completed two and one of their scheduled follow-up exercise tests, respectively. Given the observed effect between higher adherence and improved outcomes, it is more important to provide cardiac ER programs which can achieve increased adherence to the exercise intervention [8].</p> <p>Cardiac telerehabilitation using monitoring devices and remote communication with patients has now been used more and more in the long-term management of cardiovascular diseases outside the hospital environment. Providing objective feedback data and allowing patients to track their own progress can increase patients' self-management skills and thus improve their adherence. It is convenient and can reduce anxiety, improve the quality of life and prognosis of patients with low medical costs compared with conventional ER without monitoring [9-13].</p>
	6b	<p>Explanation for choice of comparators page 5</p> <p>Cardiac telerehabilitation using monitoring devices and remote communication with patients has now been used more and more in the long-term management of cardiovascular diseases outside</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		the hospital environment. Providing objective feedback data and allowing patients to track their own progress can increase patients' self-management skills and thus improve their adherence. It is convenient and can reduce anxiety, improve the quality of life and prognosis of patients with low medical costs compared with conventional ER without monitoring [9-13].
Objectives	7	Specific objectives or hypotheses page 5 This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness and safety of home-based phase-II ER under the guidance of remote electrocardiogram (ECG) monitoring system (REMS) in the management of CHF compared with conventional ER without monitoring.
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) Page 5 This study is a prospective, randomized, parallel controlled clinical trial to evaluate the effectiveness and safety of home-based phase-II ER under the guidance of remote electrocardiogram (ECG) monitoring system (REMS) in the management of CHF compared with conventional ER without monitoring.
Methods: Participants, interventions, and outcomes		
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained page 6

		<p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment.</p>
Eligibility criteria	10	<p>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) Page 6,17</p> <p>Inclusion criteria: 1. Aged 18-75 years old; 2. NYHA I-III; LVEF<50% in 6 weeks before randomization; 3. in stable condition after heart failure standard drug therapy (do not need intravenous diuretics, vasoconstrictors, vasodilators or left ventricular assist device), no fluid retention, constant weight; 4. able to perform exercise rehabilitation; 5. clearly understand the content and purpose of the study and volunteer to participate in the study and sign the informed consent form.</p> <p>Exclusion criteria : 1. exercise rehabilitation can not be carried out due to physical disability and contraindication; 2. with a contraindication to cardiopulmonary exercise test; 3. the following was happened in 3 months before admission: acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid artery or other major vascular surgery; percutaneous coronary intervention (PCI)or carotid artery angioplasty; sustained ventricular tachycardia or fibrillation; 4. coronary</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>revascularization or heart transplantation is planned; 5. persistent atrial arrhythmias ; ventricular arrhythmias were not effectively controlled (using an antiarrhythmic drug or an implantable defibrillator); 6. uncorrected primary obstructive or severe regurgitant heart valve disease, restrictive or hypertrophic cardiomyopathy; 7. II or III degree heart block or sick sinus syndrome without permanent pacemaker implantation; need implantable device therapy for heart failure; 8. obstructive or bronchospasm lung disease(such as asthma, bronchitis, etc) needing oral or inhaled bronchodilator or glucocorticoids therapy; 9. pregnant or lactating women and those planning to conceive during the trial; 10. cancer or other systemic diseases with an expected survival of less than 12 months; 11. other clinical trial drugs were taken or in other medical device trial within 30 days before admission; 12. unable to participate in this study after the clinical evaluation by investigators</p>
Interventions	11a	<p>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered page8,9</p> <p>All the patients initiate an exercise training program following the principles of exercise prescription as recommended by the American College of Sports Medicine (ACSM) and the AHA. The exercise stage order can be warm-up, main exercise, and cool-down. For the warm-up and cool-down, walking or light stretching is recommended. The main exercise is walking. Exercise training initially begins in a supervised setting and then transitions to a home-based</p>

regimen (Table 3 and Table 4) . The supervised training phase consists of 12 supervised training sessions, with a goal of 3 sessions per week. Patients have up to 1 month to complete the 12 sessions before transition to the home exercise phase. Patients are asked to exercise 5 times per week during the home exercise phase, totally 8 weeks. Patients begin exercising at a low intensity and then increase to a moderate intensity when they are able. The trial protocol allows patients to walk independently.

In the REMS group, patients wear Inticare-MC-06 ECG monitors when exercising at home to ensure that exercise intensity is within the ranges set for them and are instructed on how to monitor their own exercise training at the beginning of the trial. During the exercise, the monitor can evaluate whether patients reach the intensity and time of the preset exercise prescription according to the heart rate. If the speed is not enough or the intensity exceeds the preset value, the system can remind the patient promptly to adjust the intensity, including speed and time course, so as to ensure the patient to exercise according to the prescription. If arrhythmia occurs during exercise, the system will alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and upload it in real time. Specialists will give an analysis report. The system will give an early warning to both patients and their doctors if the arrhythmia is risky. Doctors can check the data of their patients outside hospital, know about their conditions and give advice in time.

The heart rate reserve (HRR) method is used to guide exercise intensity. Peak heart rate is derived from a patient's most recent exercise test, and the resting heart rate is taken after 5 minutes of quiet seated rest. For the first 6 supervised training sessions, the training heart rate range is

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>computed at 60% of the HRR (resting heart rate + 0.6 [peak heart rate-resting heart rate]). Then training intensity is increased to 70% of the HRR for the rest of the supervised exercise training sessions. For the home-based exercise training phase, patients are asked to perform 40 minutes of aerobic exercise. In the REMS training arm, the training intensity should be maintained at 60% to 70% of the HRR. While during the whole phase of the conventional rehabilitation arm, the training intensity is not monitored.</p>
	11b	<p>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</p> <p>Page 8</p> <p>If a cardiogram such as arrhythmia occurs during exercise, the system will alert the patient to stop or suspend exercise, or adjust the intensity of exercise, and upload it in real time. The data will be transformed to the data center, while specialist will give an analysis for that report. The unique algorithm can analyze the data in real time and detect suspected arrhythmias, then give the alarm and transfer data to cloud platform for doctors to check and confirm the disease. In addition, when patients have chest discomfort, palpitation and dizziness, they can mark the ECG data through One-Tap Marking button and send the data for doctors to check and give corresponding diagnosis. At the end of the monitoring, a report will be provided.</p>
	11c	<p>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</p>

		<p>Page 9,10</p> <p>During the training phase, participants will be asked to exercise strictly according to the prescription and record each exercise process with designed cards. Investigators will make telephone reminders before each visit and then give face-to-face reminders at each study visit emphasizing the importance of adherence. Compliance of ER in subjects are expressed in rate.</p>
	11d	<p>Relevant concomitant care and interventions that are permitted or prohibited during the trial</p> <p>Page 9</p> <p>Participants in both groups will continue standard therapy for HF. The medication should remain unchanged during the trial, while the dosage should be adjusted in case of adverse events. All procedures will be determined by physicians following the clinical guidelines.</p>
Outcomes	12	<p>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</p> <p>Page 10</p> <p>The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO₂ peak) (baseline vs 3 m). The secondary outcomes are: (1) difference in the meters walked in the 6-min Walk Test (6MWT); (2) improvement in heart function assessed by NYHA classifications; (3) improvement in echocardiographic parameters of systolic and diastolic function; (4) changes in biomarkers, including brain natriuretic peptide (BNP) / N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and Troponin-T/I; (5) changes in major adverse cardiovascular events (MACE) including worsening HF event, HF hospitalization, myocardial infarction, stroke, revascularization and cardiovascular mortality; (6) qualitative evaluation of patients' adherence to the rehabilitation program. The investigators will also use several validated psychometric instruments to measure health-related quality of life and depression. These measurements include</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		HF Symptom Scale, Minnesota Living with Heart Failure Questionnaire (MLHFQ), 36-Item Short Form Health Survey (SF-36), Beck Depression Inventory-II (BDI-II) and General Self-Efficacy Scale (GSE).
Participant timeline	13	<p>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended</p> <p>Figure 1</p> <pre> graph TD A[Patients with criteria] --> B[Patients sign informed consent] B --> C[Baseline CPET+6MWT] C --> D[1:1 Randomization (n=120)] D --> E[Remote monitoring rehabilitation group (n=60)] D --> F[Conventional rehabilitation group (n=60)] E --> G[Exercise training by REMS +standard therapy (3m)] F --> H[Exercise training without Monitoring +standard therapy (3m)] G --> I[Safety and effectiveness evaluation] H --> I </pre>

Sample size	14	<p>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations Page 6</p> <p>The target enrollment for the trial is 120 patients. A total of 500 patients with HF (NYHA grade I-III) are treated in our hospital every year, which can be used as a screening sample. Calculated according to the lower screening rate (50%) and the designed entry criteria, the sample size that can be completed is estimated to be 100 patients. Referring to the previous foreign literature, the compliance of ER in 3 months is 70-80%. The initial screening sample size of this study is at least 120 cases, 60 cases in each group.</p>
Recruitment	15	<p>Strategies for achieving adequate participant enrolment to reach target sample size Page 6</p> <p>Screening will continue until the target population is achieved. A recruitment advertisement has also been utilized in our hospital.</p>
Methods: Assignment of interventions (for controlled trials)		
Allocation:		
Sequence generation	16a	<p>Method of generating the allocation sequence (eg, computer-generated random numbers) and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enroll participants or assign interventions</p> <p>Page 7</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		generate a random sequence of 120 numbers using SAS 9.4 software. The random sequence will be put into sealed envelopes by staff not involved with the study to avoid selecting bias.
Allocation concealment mechanism	16b	<p>Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned Page 7</p> <p>After providing informed consent and undergoing baseline testing (echocardiogram and CPET), patients are randomized in a 1:1 ratio to either REMS rehabilitation group or the conventional rehabilitation group according to the time order of the patients' entry. Allocation concealment will be ensured and the randomization code will not be released until the patient has been recruited into the trial, which takes place after all baseline measurements have been completed. Researchers involved in participants' assessments will be blinded to treatment allocation.</p>
Implementation	16c	<p>Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions Page 6,7</p> <p>China-Japan Friendship Hospital clinical research data management platform is commissioned to generate a random sequence of 120 numbers using SAS 9.4 software.</p> <p>Patients will be recruited consecutively from the outpatient service of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p>
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts) and how

		Page 10,11 Researchers involved in participants' assessments will be blinded to treatment allocation. All individuals involved in data management and analysis will be blinded to treatment allocation.
	17b	If blinded, circumstances under which unblinding is permissible and procedure for revealing a participant's allocated intervention during the trial
		N/A
Methods: Data collection, management, and analysis		
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol Page10,11 All patients' data will be recorded by trained clinical researchers using a standardized case report form (CRF). Original data should be recorded timely and accurately. Laboratory reports copies should also be kept. All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality. Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers. All individuals involved in data management and analysis will be blinded to treatment allocation. Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Page 9,10</p> <p>During the training phase, participants will be asked to exercise strictly according to the prescription and record each exercise process with designed cards. Investigators will make telephone reminders before each visit and then give face-to-face reminders at each study visit emphasizing the importance of adherence.</p>
Data management	19	<p>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol</p> <p>Page10,11</p> <p>All patients' data will be recorded by trained clinical researchers using a standardized case report form (CRF). Original data should be recorded timely and accurately. Laboratory reports copies should also be kept. All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality. Data managers from Beijing Cardiar Technology, China are responsible for the data entry and management. The database is established by PHP language under Linux system. Two data managers perform double entry independently and proofread to ensure the data accuracy. China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers. All individuals involved in data management and analysis will be blinded to treatment allocation. Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.</p>
Statistical methods	20a	<p>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol</p> <p>Page 11,12</p> <p>Continuous variables will be presented as the mean \pmstandard deviation (SD), median or interquartile range (IQR). Baseline characteristics of the cohort will be summarized using</p>

		<p>descriptive statistics. Whether imbalances exist will be analyzed between groups. Comparison of numerical variables between the two groups is made using Student's t-test for independent samples when normally distributed. Categorical variables will be described as frequencies and percentages and compared using χ^2 test. Mann-Whitney U test will be used if data are not normally distributed.</p> <p>Analysis of outcomes will be conducted according to the intention-to-treat (ITT) principle. We will use three analysis sets: full analysis set (FAS), per protocol set (PPS) and safety set. The FAS includes all patients randomized, and the PPS consists of all patients who complete the treatment protocol. The safety set consists of patients who receive at least one treatment with safety records after randomization. Dropouts will be included in the analysis by modern imputation methods for missing data.</p> <p>All statistical tests will be 2-tailed. $P < 0.05$ is considered statistically significant. All statistical analyses will be completed by Beijing Zhengyuan Technology Co., Ltd using SAS 9.4 software.</p>
	20b	<p>Methods for any additional analyses (eg, subgroup and adjusted analyses) page 12</p> <p>Dropouts will be included in the analysis by modern imputation methods for missing data.</p>
	20c	<p>Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</p> <p>Page 11,12</p> <p>Analysis of outcomes will be conducted according to the intention-to-treat (ITT) principle. We will use three analysis sets: full analysis set (FAS), per protocol set (PPS) and safety set. The FAS includes all patients randomized, and the PPS consists of all patients who complete the treatment protocol. The safety set consists of patients who receive at least one treatment with safety records after randomization.</p>
Methods: Monitoring		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</p> <p>Page11</p> <p>China-Japan Friendship Hospital clinical research data management platform is responsible for data monitoring, which is independent of the study organizers.</p>
	21b	<p>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</p> <p>N/A</p>
Harms	22	<p>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</p> <p>Page 11</p> <p>All adverse events that occurred during the 3-month study period will be reported in the final paper. A serious adverse event is defined as any untoward medical occurrence resulting in hospitalization or which results in a life-threatening problem, death, or disability. Adverse events will be defined as any untoward occurrences in study participants, potentially related to implementation of the study protocol. All serious and unexpected adverse events will be reported to the Ethics Committee as required.</p>
Auditing	23	<p>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</p> <p>N/A</p>
Ethics and dissemination		
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval

		<p>Page 3</p> <p>This study was approved by Ethics Committee of China-Japan Friendship Hospital for Clinical Research (No. 2018-55-K39) .</p>
Protocol amendments	25	<p>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</p> <p>Page 5</p> <p>If there is any amendment to the protocol, approval must be sought again from the Ethics Committee.</p>
Consent or assent	26a	<p>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</p> <p>Page 6</p> <p>Patients will be recruited consecutively from the outpatient clinic of Cardiology Department and Integrative Cardiology Department in China-Japan Friendship Hospital by attending physicians responsible for recruitment, who will obtain written consent from patients willing to participate in the trial.</p>
	26b	<p>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</p> <p>N/A</p>
Confidentiality	27	<p>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</p> <p>Page 11</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		All CRFs will be stored in locked file cabinets in areas with limited access. All laboratory specimens will be identified by a coded number to maintain participant confidentiality.
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site Page 14 The authors declare that they have no competing interests.
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators Page 11 Principal investigators will have direct access to data sets. Data dispersed to project team members will be blinded of any identifying participant information.
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care and for compensation to those who suffer harm from trial participation N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions Page 3 The results of this study will be disseminated via peer-reviewed publications and presentations at conferences.
	31b	Authorship eligibility guidelines and any intended use of professional writers N/A Topics suggested for publication will be circulated to the principal investigators.

		No intended use of professional writers.	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code No later than 3 years after the collection of the 3m postrandomization interviews, we will deliver a deidentified data set to an appropriate data archive for sharing purposes.	N/A
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates A Chinese version of informed consent (V1.1, 20180208) has been reviewed and approved by the Ethics Committee of China-Japan Friendship Hospital for Clinical Research.	N/A
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable N/A	